0001553350-21-000382.txt : 20210513 0001553350-21-000382.hdr.sgml : 20210513 20210513130356 ACCESSION NUMBER: 0001553350-21-000382 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210513 DATE AS OF CHANGE: 20210513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EVOLUTIONARY GENOMICS, INC. CENTRAL INDEX KEY: 0000884363 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 264369698 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54129 FILM NUMBER: 21918343 BUSINESS ADDRESS: STREET 1: 1026 ANACONDA DRIVE CITY: CASTLE ROCK STATE: CO ZIP: 80108 BUSINESS PHONE: (720) 900-8666 MAIL ADDRESS: STREET 1: 1026 ANACONDA DRIVE CITY: CASTLE ROCK STATE: CO ZIP: 80108 FORMER COMPANY: FORMER CONFORMED NAME: Fona, Inc. DATE OF NAME CHANGE: 20100907 FORMER COMPANY: FORMER CONFORMED NAME: PHONE A HOME CORP DATE OF NAME CHANGE: 19930708 FORMER COMPANY: FORMER CONFORMED NAME: FONAHOME CORP DATE OF NAME CHANGE: 19930328 10-Q 1 fnam_10q.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

———————

FORM 10-Q

———————

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO __________

EVOLUTIONARY GENOMICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-54129	26-4369698
(State of other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification N)

1026 Anaconda Drive, Castle Rock CO 80108

(Address of Principal Executive Office)

Registrants telephone number, including area code: (720) 900-8666

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A	N/A	N/A

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $.001 par value

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of March 31, 2021, the Registrant had 5,881,898 shares of common stock, $.001 par value, 577,063 shares of Series A-1 preferred stock, $.001 par value and 102,860 shares of Series A-2 preferred stock, $.001 par value outstanding. The Registrant’s common stock trades on the OTC Markets under the trading symbol “FNAM”.

EVOLUTIONARY GENOMICS, INC.

INDEX

		Page Number

	PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	1

	Condensed and Consolidated Balance Sheets as of March 31, 2021 (unaudited) and December 31, 2020	2

	Condensed and Consolidated Statements of Operations, Three Months ended March 31, 2021 and 2020 (unaudited)	3

	Condensed and Consolidated Statements of Stockholders’ Deficit for the Quarterly Periods Ended March 31, 2021 and 2020 (unaudited)	4

	Condensed and Consolidated Statements of Cash Flows, Three Months ended March 31, 2021 and 2020 (unaudited)	5

	Notes to Condensed and Consolidated Financial Statements	6

Item 2.	Management's Discussion and Analysis of Financial Conditions and Results of Operations	14

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	19

Item 4.	Controls and Procedures	19

	PART II. OTHER INFORMATION

Item 1,	Legal Proceedings	20

Item 1A.	Risk Factors	20

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20

Item 3.	Defaults Upon Senior Securities	20

Item 4.	Mine Safety Disclosures.	20

Item 5.	Other Information	20

Item 6.	Exhibits	20

PART I. FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS

The accompanying financial statements have been prepared by Evolutionary Genomics, Inc., without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position of the Company as of March 31, 2021 and for the three month periods ended March 31, 2021 and 2020 have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed and consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2020 audited financial statements. The results of operations for these interim periods are not necessarily indicative of the results for the entire year.

Evolutionary Genomics, Inc. and Subsidiary

Condensed and Consolidated Balance Sheets

	March 31,			December 31,
	2021			2020
	(unaudited)
ASSETS

Current assets
Cash	$	97,558		$	215,836
Prepaid expenses		58,292			61,757
Total current assets		155,850			277,593

Non-current assets
Property and equipment, net		42,747			50,763
Intangible assets, net		3,412,656			3,664,343
Total non-current assets		3,455,403			3,715,106
Total assets	$	3,611,253		$	3,992,699

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities
Accounts payable and accrued expenses	$	4,135		$	3,164
Total current liabilities		4,135			3,164

Long-term liabilities
Notes payable		2,322,226			2,245,831
Total liabilities		2,326,361			2,248,995
Commitments and contingencies
Preferred Stock subject to possible redemption, $0.001 par value,
20,000,000 authorized at March 31, 2021 and December 31, 2020
Series A-1 Convertible Preferred Stock, $0.001 par value; 600,000
shares authorized, 577,063 shares issued and outstanding at
March 31, 2021 and December 31, 2020; liquidation
preference at March 31, 2021 of $4,272,380		3,029,579			3,029,579
Series A-2 Convertible Preferred Stock, $0.001 par value; 200,000
shares authorized, 102,860 shares issued and outstanding at
March 31, 2021 and December 31, 2020; liquidation
preference at March 31, 2021 of $622,457		540,015			540,015
Total preferred stock subject to possible redemption		3,569,594			3,569,594
Stockholders' deficit
Preferred Stock		1,307,620			1,236,228
Common Stock, $0.001 par value; 780,000,000 shares authorized, 5,881,898
shares issued and outstanding at March 31, 2021 and December 31, 2020		5,882			5,882
Additional paid-in capital		11,999,090			12,015,552
Accumulated deficit		(15,597,294	)		(15,083,552	)
Total stockholders' deficit		(2,284,702	)		(1,825,890	)
Total liabilities and stockholders' deficit	$	3,611,253		$	3,992,699

The accompanying notes are an integral part of the consolidated financial statements.

Evolutionary Genomics, Inc. and Subsidiary

Condensed and Consolidated Statements of Operations

For the Three Months ended March 31, 2021 and 2020

(unaudited)

	2021			2020

Grant revenue	$	—		$	12,500

Operating expenses
Research and development		96,815			93,222
Salaries and benefits		92,430			92,430
General and administrative		324,605			56,665
Total operating expenses		513,850			242,317

Operating loss		(513,850	)		(229,817	)

Other income (expenses):
Investment income		108			1
Unrealized loss on investments		—			(12,000	)
Total other income (expenses)		108			(11,999	)
Loss before income taxes		(513,742	)		(241,816	)
Income taxes		—			—
Net loss		(513,742	)		(241,816	)
Preferred stock dividend		(71,392	)		(71,391	)
Net loss attributable to common stockholders	$	(585,134	)	$	(313,207	)

Net loss per common share, basic and diluted	$	(0.10	)	$	(0.05	)

Weighted average common shares outstanding, basic and diluted		5,881,898			5,881,898

The accompanying notes are an integral part of the consolidated financial statements.

Evolutionary Genomics, Inc. and Subsidiary

Condensed and Consolidated Statement of Stockholders' Deficit

	Three Months Ended March 31, 2021
	Common Stock				Preferred		Additional			Accumulated			Stockholders'
	Shares		Amount		Dividend		Paid-In Capital			Deficit			Deficit

Balance, December 31, 2020		5,881,898	$	5,882	$	1,236,228	$	12,015,552		$	(15,083,552	)	$	(1,825,890	)
Stock compensation		—		—		—		54,930			—			54,930
Preferred stock dividends		—		—		71,392		(71,392	)		—			—
Net loss		—		—		—		—			(513,742	)		(513,742	)
Balance, March 31, 2021		5,881,898	$	5,882	$	1,307,620	$	11,999,090		$	(15,597,294	)	$	(2,284,702	)

	Three Months Ended March 31, 2020
	Common Stock				Preferred		Additional			Accumulated			Stockholders'
	Shares		Amount		Dividend		Paid-In Capital			Deficit			Deficit

Balance, December 31, 2019		5,881,898	$	5,882	$	950,661	$	12,081,401		$	(13,371,669	)	$	(333,725	)
Stock compensation		—		—		—		54,930			—			54,930
Preferred stock dividends		—		—		71,391		(71,391	)		—			—
Net loss		—		—		—		—			(241,816	)		(241,816	)
Balance, March 31, 2020		5,881,898	$	5,882	$	1,022,052	$	12,064,940		$	(13,613,485	)	$	(520,611	)

The accompanying notes are an integral part of the consolidated financial statements.

Evolutionary Genomics, Inc. and Subsidiary

Condensed and Consolidated Statements of Cash Flows

For the Three Months ended March 31, 2021 and 2020

(unaudited)

	2021			2020
Cash flows from operating activities:
Net loss	$	(513,742	)	$	(241,816	)
Adjustments to reconcile net loss to net
cash flows from operating activities
Depreciation and amortization		259,703			10,180
Stock-based compensation		54,930			54,930
Unrealized loss on investments		—			12,000
Changes in operating assets and liabilities:
Accounts receivable		—			6,845
Prepaid expenses		3,465			8,913
Accounts payable and accrued expenses		971			114,160
Cash flows from operating activities		(194,673	)		(34,788	)

Cash flows from investing activities:
Cash flows from investing activities		—			—

Cash flows from financing activities:
Proceeds from issuance of notes payable		76,395			—
Cash flows from financing activities		76,395			—

Net change in cash		(118,278	)		(34,788	)

Cash, beginning of period		215,836			45,441

Cash, end of period	$	97,558		$	10,653

Supplemental cash flow information
Preferred stock dividend accrual	$	71,392		$	71,391

The accompanying notes are an integral part of the consolidated financial statements.

EVOLUTIONARY GENOMICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED AND CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2021 AND 2020 (Unaudited)

Note 1: Business Activity

Evolutionary Genomics, Inc. (the “Company,” “We,” or “Our”) has developed a technology platform, the Adapted Traits Platform (“ATP”), to identify commercially valuable genes that control important traits in animals and plants. We are using the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. Our platform identifies key genes that have changed successfully to impart new or improved traits.

In the past, the Company performed research on behalf of governmental organizations, non-profit foundations and commercial entities and received revenue from grants and commercial research contracts. We have not received any revenue from these grant arrangements since early 2020. The Company now focuses on research projects that may lead to long-term licensing arrangements with agricultural seed companies and crop producers as with our soybean and banana projects. These projects take several years to develop, and successful commercialization may take many years to produce license royalty payments. Our banana project, in cooperation with Dole Food Company is an example that has resulted in notes payable funding for the development phase of our banana genes and may result in a long-term royalty bearing license once the development phase is complete.

During 2014, the Company purchased 75.16% of the outstanding stock of Fona, Inc., (“Fona”) a public shell company. Since Fona was a public shell company which did not constitute a business and the purchase was done in contemplation of a reverse merger, the Company accounted for the payment as a distribution to Fona shareholders. The Company also entered into an Agreement and Plan of Merger (the “Merger”), which was consummated on October 19, 2015. As a result of the Merger, Evolutionary Genomics, Inc. became a wholly owned subsidiary of Fona. For accounting purposes, the merger was treated as a reverse acquisition with Evolutionary Genomics, Inc. as the acquirer and Fona as the acquired party. Subsequent to the Merger, Fona was renamed Evolutionary Genomics, Inc. and our subsidiary was renamed from Evolutionary Genomics, Inc. to EG Crop Science, Inc.

Note 2: Summary of Significant Accounting Policies

Principals of Consolidation: These consolidated financial statements include the accounts of Evolutionary Genomics, Inc. and its wholly owned subsidiary. All material intercompany transactions and balances have been eliminated.

Use of Estimates: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

These consolidated financial statements have been prepared on the basis of going concern. Management’s plans to address the Company’s liquidity are discussed further in Note 13.

Cash: The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less when purchased to be cash.

Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided for by the straight-line method over three- to seven-year estimated useful lives for software, furniture and fixtures and equipment. Maintenance and repairs are expensed as incurred; major renewals and betterments that extend the useful lives of property and equipment are capitalized. When property and equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is recognized.

Long-Lived Assets: The long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. An impairment loss is measured and recorded to the extent that the carrying amount of the asset exceeds its estimated fair value. No asset impairment was recorded during the three months ended March 31, 2021 and 2020.

EVOLUTIONARY GENOMICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED AND CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2021 AND 2020 (Unaudited)

Intangible Assets: Intangible assets include acquired research in progress and patents on the Company’s core technology for gene identification. Patents are amortized over their expected useful life of 20 years using the straight-line method. Acquired research in progress was placed into service on August 19, 2020 in conjunction with the Development and Commercialization Agreement and is being amortized over four years consistent with the term of the Dole agreement using the straight-line method. Costs incurred to renew intangible assets are expensed in the period incurred, while costs incurred to extend the lives of patents are capitalized and amortized over the remaining useful life of the asset. Intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any intangible assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. No impairment was recorded during the three months ended March 31, 2021 and 2020.

Revenue Recognition: Grant revenue consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by us. However, these amounts are subject to change upon review by federal and non-profit foundations prior to receipt of invoice amounts submitted. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed.

Income Taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Management regularly assesses the likelihood that deferred tax assets will be recovered from future taxable income, and to the extent management believes that it is more likely than not that a deferred tax asset will not be realized, a valuation allowance is established. When a valuation allowance is established, increased or decreased, an income tax charge or benefit is included in the consolidated financial statements and net deferred tax assets are adjusted accordingly. As of March 31, 2021 and December 31, 2020, a full valuation allowance has been established on the net deferred tax asset.

Under the Income Tax topic of the ASC, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company has no accruals for uncertain tax benefits.

Stock-Based Compensation: The Company accounts for stock option awards in accordance with ASC 718. The estimated grant-date fair value of stock-based awards is expensed over the requisite service period, which is typically equivalent to the vesting term of the award.

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services received follows the provisions of ASC Topic 718. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement.

Research and Development: Research and development costs are expensed as incurred. In instances where we enter into agreements with third parties for research and development activities, we may prepay for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed.

Net Loss Per Common Share: Basic net (loss) income per common share excludes any dilutive effects of equity instruments. We compute basic net (loss) income per common share using the weighted average number of common shares outstanding during the period. We compute diluted net (loss) income per common share using the weighted average number of common shares and common stock equivalents outstanding during the period. For the three months ended March 31, 2021, common stock equivalents including 679,923 shares of convertible preferred stock and options for 1,081,667 shares of common stock were excluded because their effect was anti-dilutive. For the three months ended March 31, 2020, common stock equivalents including 679,923 shares of convertible preferred stock, options for 1,081,667 shares of common stock and warrants for 110,856 shares of common stock were excluded because their effect was anti-dilutive.

EVOLUTIONARY GENOMICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED AND CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2021 AND 2020 (Unaudited)

Note 3: New Accounting Standards

Recently Issued Accounting Standards

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments,” which requires entities to estimate all expected credit losses for certain types of financial instruments, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The updated guidance also expands the disclosure requirements to enable users of financial statements to understand the entity’s assumptions, models and methods for estimating expected credit losses over the entire contractual term of the instrument from the date of initial recognition of that instrument. This guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within that reporting period and is not expected to have an impact on the Company’s consolidated financial statements.

Note 4: Fair Value Measurements

The Company complies with the provisions of ASC 820, in measuring fair value and in disclosing fair value measurements at the measurement date. ASC 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements required under other accounting pronouncements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements also reflect the assumptions market participants would use in pricing an asset or liability based on the best information available. Assumptions include the risks inherent in a particular valuation technique (such as a pricing model) and/or the risks inherent in the inputs to the model.

ASC 820 provides three levels of the fair value hierarchy as described below:

Level 1 Inputs	–	Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 Inputs	–	Observable market-based inputs, other than quoted prices in active markets for identical assets or liabilities.
Level 3 Inputs	–	Unobservable inputs that are supported by little or no market activity.

When determining the fair value measurements for assets or liabilities required or permitted to be recorded at and/or marked to fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability. When possible, the Company looks to active and observable markets to price identical assets. When identical assets are not traded in active markets, the Company looks to market observable data for similar assets.

The carrying value of financial instruments, including cash, receivables, accounts payable, and accrued expenses, approximates their fair value at March 31, 2021 and December 31, 2020, due to the relatively short-term nature of these instruments.

EVOLUTIONARY GENOMICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED AND CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2021 AND 2020 (Unaudited)

Note 5: Property and Equipment

Property and equipment is comprised of the following:

	March 31,			December 31,
	2021			2020
Equipment	$	432,499		$	432,499
Software		63,179			63,179
Furniture and fixtures		7,987			7,987
		503,665			503,665
Accumulated depreciation		(460,918	)		(452,902	)
Property and equipment, net	$	42,747		$	50,763

Depreciation expense for the three months ended March 31, 2021 and 2020 was $8,016 and $9,529, respectively.

Note 6: Intangible Assets

Intangible assets are comprised of the following:

	March 31,			December 31,
	2021			2020
Acquired research in progress - definite lived	$	4,016,596		$	4,016,596
Patents		52,045			52,045
Accumulated amortization		(655,985	)		(404,298	)
Intangible assets, net	$	3,412,656		$	3,664,343

The Company expects to recognize amortization expense related to its acquired research in progress and patents according to the following:

Year Ending	Amortization
December 31, 2021	$	755,064
December 31, 2022		1,006,751
December 31, 2023		1,006,751
December 31, 2024		638,105
December 31, 2025		2,602
Thereafter		3,383
Total	$	3,412,656

Amortization expense for the acquired research in progress and patents during the three months ended March 31, 2021 and 2020 was $251,687 and $651, respectively.

In its merger completed on October 19, 2015, the Company acquired research in progress. The value of the acquired research in progress was based upon several factors including, evaluation of other intangible assets, the purchase price, estimated future cash flows, and the amounts expended on the research to date. The research in progress was the identification and validation of genes to provide pest and disease resistance to plants performed by EG I. With the banana development project contract in place and the expected marketing of our soybean genes in mid-2021, the Company placed this asset in service on August 19, 2020. Additional costs to complete the soybean research are expected to be approximately $65,000, which will be expensed as incurred. The timing and cost of additional research may vary from these estimates as the success of the research is subject to many factors outside of the Company’s control.

EVOLUTIONARY GENOMICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED AND CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2021 AND 2020 (Unaudited)

Note 7: Notes Payable

Small Business Administration (“SBA”) Paycheck Protection Program (“PPP”): On February 22, 2021, the Company received $76,395 in proceeds from the PPP, which was created under the Coronavirus Aid, Relief and Economic Security Act (CARES). Under the program, the Company may apply for forgiveness of the debt based on the use of the proceeds over an 8-week or a 24-week period following funding of the loan. To the extent that the loan is not forgiven, the loan accrues interest at 1 percent and has monthly payments of $1,792.53 starting July 22, 2022. The Company expects this loan to be forgiven within the year ending December 31, 2021 after it meets the requirements of the forgiveness provisions.

SBA Economic Injury Disaster Loan: On June 5, 2020, the Company received a $3,000 Economic Injury Disaster Loan (“EIDL”) advance and $150,000 in proceeds from the SBA’s EIDL Program. Installment payments, including interest at the rate of 3.75% per annum, of $731 monthly over thirty years from the date of the promissory note will begin twelve months from the date of the promissory note (June 5, 2022). The Company granted to the SBA a continuing security interest in all tangible and intangible personal property. The Company may not make any distribution of assets of the Company to any shareholder without the written consent of the SBA. As of March 31, 2021, the Company recognized $4,135 of accrued interest on the note.

Dole Food Company:

On August 19, 2020, the Company entered into a Development and Commercialization Agreement (“DCA”) with Dole Food Company (“Dole”) for the development of our banana genes. The DCA provides for payments from Dole to the Company of $800,000 upon execution, $800,000 by the twelve-month anniversary (August 19, 2021), $250,000 by the thirty-six month anniversary and $250,000 by the forty-eight month anniversary. Dole will also reimburse the Company for costs incurred at the University of Wisconsin-Madison (“UW”) not to exceed $2,200,000 in coordination with the Standard Research Agreement that the Company entered into with UW on September 18, 2020. The agreement with UW includes payments from the Company to UW in the amount of $2,159,719 over the two-year expected term of the project. If the UW research is successful, Dole expects to incur costs of approximately $750,000 to perform field trials.

The DCA also specifies that the Company will execute notes payable to Dole for the funding that Dole is providing up to $5,050,000. Upon receipt of $800,000 on August 26, 2020 and $1,295,831 on December 29, 2020, the Company executed the notes under this DCA and recorded them as long-term notes payable for financial statement purposes. The notes are non-interest bearing and allow Dole to offset fifty percent of future royalty payments to the Company by reducing the amount of principal due on these notes. Other than this offset of future royalty payments, repayment of principal and interest is only required in the case of termination of the DCA by Dole for cause.

Note 8: Stockholders’ Equity and Warrants

The Amended and Restated Certificate of Incorporation of the Company dated October 19, 2015 authorized the issuance of 800,000,000 shares of all classes of stock including 780,000,000 shares of Common Stock having a par value of $0.001 per share and 20,000,000 shares of Preferred Stock having a par value of $0.001 per share, 600,000 of which were designated as Series A-1 Convertible Preferred Stock (“Series A-1”) and 200,000 of which were designated as Series A-2 Convertible Preferred Stock (“Series A-2”). The Board of Directors, without a vote of the shareholders, is authorized to issue additional shares of Preferred Stock in series and to establish the characteristics thereof.

Liquidation: Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of the Series A-1 and Series A-2 shall be entitled to receive out of the assets of the Company for each share of Series A-1 and Series A-2 an amount equal to its stated value, $5.25 per share as of March 31, 2021 and December 31, 2020, plus any accrued but unpaid dividends before any distribution or payment shall be made to the holders of any other class or series of stock of the Company that ranks junior to the Series A-1 and Series A-2. The holders shall be entitled to convert their shares of Series A-1 and Series A-2 into Common Stock at any time prior to the consummation of a Liquidation. This is considered a contingent redemption feature.

Conversion: The holders of Series A-1 and Series A-2 may convert their shares into shares of Common Stock, at the option of the holder, on a one-share-for-one-share basis and shall be subject to certain adjustments at any time.

EVOLUTIONARY GENOMICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED AND CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2021 AND 2020 (Unaudited)

Optional Redemption; Sinking Fund Account: The Company may elect to redeem some or all of the then outstanding shares of Series A-1, (i) for cash in an amount equal to the liquidation preference per share, $5.25 per share as of March 31, 2021, subject to adjustment and (ii) by issuing one share, subject to adjustment, of Common Stock for each share of Series A-1 and Series A-2 outstanding being redeemed. 50% of all licensing fees received by the Company will be deposited into a separate sinking fund for use in an optional redemption. As of March 31, 2021, no licensing revenue has been received under these provisions and no sinking fund account has been established.

Dividends: The Company shall pay to the holders of the Series A-1 and Series A-2 dividends at the rate of 8% per annum and the Company has accrued these dividends since issuance of the Series A-1 and Series A-2. The dividend amount shall accrue and shall be payable in shares of Common Stock upon the conversion of the Series A-1 and Series A-2, or upon the redemption of the Series A-1 and Series A-2. No dividends shall be paid on any Common Stock of the Company or any capital stock of the Company that ranks junior to the Series A-1 and Series A-2 until dividends of Series A-1 and Series A-2 been paid. As of March 31, 2021, there were $1,307,620 in accrued stock dividends.

Voting: The holders of the Series A-1 and Series A-2 are entitled to vote on all matters submitted to the stockholders for a vote on an as-if-converted to Common Stock basis, with all stockholders voting as a single class.

Note 9: Stock-Based Compensation

The Company grants stock-based instruments under the 2015 Stock Incentive Plan (“Plan”) for which 1,400,000 shares of the Company’s Common Stock has been reserved. The Plan allows for the issuance of incentive stock options and non-qualified stock options with a maximum contractual term of 10 years. Shares and options that are cancelled are available for reissuance under the Plan. For three months ended March 31, 2021 and 2020, the Company recorded compensation costs for stock options of $54,930. Stock options are generally issued with an exercise price at or above the estimated per-share value of the Company’s Common Stock. The Company granted no options during the three months ended March 31, 2021 and 2020.

Management has valued the options at their date of grant utilizing the Black-Scholes option pricing model. As of the issuance of the outstanding options, there was not a public market for the Company’s shares. Accordingly, the Company utilized the value obtained in equity transactions with unrelated parties to estimate the fair value of the Company’s Common Stock on the date of grant. Volatility of the underlying common shares was determined based on the historical volatility for similar companies that are actively traded in the public markets for a term consistent with the expected life of the options. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options on the date of the grant. Due to the lack of sufficient historical activity, the expected life of the options was estimated using the formula set forth in Securities and Exchange Commission SAB 107.

EVOLUTIONARY GENOMICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED AND CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2021 AND 2020 (Unaudited)

The following table summarizes the status of the Company’s aggregate stock options granted:

	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Term(Years)		Total Intrinsic Value

Balance, January 1, 2020		1,081,667	$	1.74		7.67
Granted		—		—		—
Exercised		—		—		—
Cancelled		—		—		—

Balance, December 31, 2020		1,081,667	$	1.74		6.67

Balance, January 1, 2021		1,081,667	$	1.74		6.67
Granted		—		—		—
Exercised		—		—		—
Cancelled		—		—		—

Balance, March 31, 2021		1,081,667	$	1.74		6.42	$	—

Exercisable at March 31, 2021		688,332	$	1.85		5.19	$	65,333

During the three months ended March 31, 2021 and 2020, options for 0 and 0 shares vested, respectively. As of March 31, 2021 there was $350,520 of unrecognized compensation cost related to share-based compensation arrangements that will be recognized through the year ending December 31, 2022.

Note 10: Commitments and Contingencies

Officer Indemnification: Under the Company’s organizational documents, the Company’s officers, employees, and directors are indemnified against certain liabilities arising out of the performance of their duties. The Company’s maximum exposure under these arrangements is unknown, as this would involve future claims that may be made against the Company that have not yet occurred. However, based on experience, the Company expects any risk of loss to be remote. The Company also has an insurance policy for its directors and officers to insure them against liabilities arising from their performance in their positions with the Company.

Lease Commitments: The Company leases its operating facility and pays its rent in monthly installments. The lease was renewed in June 2016 for a period of twelve months and monthly rentals for the period of July 1, 2016 through March 31, 2021 are $2,378 per month which continues on a month-to-month basis. There is no minimum lease commitment as of March 31, 2021. Renewals after June 30, 2017 are by mutual agreement. The Company’s rent expense for the three months ended March 31, 2021 and 2020 was $7,134.

Royalty: Effective March 1, 2012, the Company entered into an Agreement for Contract Services with SmithBucklin Corporation (the “Contractor”) on behalf of the United Soybean Board. The contract includes the payment of certain royalties, as defined in the Agreement.

EVOLUTIONARY GENOMICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED AND CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2021 AND 2020 (Unaudited)

The Company is obligated to pay royalties to the United Soybean Board of 10% of the sale of products derived from the soybean genes that were the subject of the research performed by the Contractor or from royalties received by the Company from the sale of products by a third party not to exceed 150% of the total amount paid to the Contractor under this Agreement. The Company has recognized to date grant revenue from the contract of $262,400 as of March 31, 2021, thus limiting any future royalties as of March 31, 2021 to a total of $393,600. The Company has not accrued or paid any royalties under the terms of the Agreement as of and during the three months ended March 31, 2021 because it has not received any revenue from the sale of products to date.

Other Commitments: On September 18, 2020, the Company entered into a Standard Research Agreement with UW for the development of our banana genes. The agreement includes payments from the Company in the amount of $2,159,719 over the two-year expected term of the project. These costs will be reimbursed, in the form of notes payable by Dole in accordance with our DCA.

Note 11: Related Parties and Transactions

Steve B. Warnecke: Mr. Warnecke is the Company’s Chief Executive Officer and Chairman of the Board and owns, directly or indirectly, 1,902,088 shares or 29.45% of the Common Stock outstanding as of March 31, 2021.

Note 12: Concentrations

Considerations of Credit Risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains its cash balances at high-credit, quality financial institutions. The balances, at times, may exceed federally insured limits. The Company routinely monitors the credit quality of its customers.

Note 13: Liquidity

As of March 31, 2021, the Company had $97,558 in bank accounts. The Company’s current projections for cash required in operations over the twelve months ending March 31, 2022 is $1,323,669. This raises substantial doubt as to the Company’s ability to continue as a going concern.

To address these factors, management believes that it will secure additional funding to meet prospective cash requirements. Management believes the Company’s existing cash balances along with funding from our agreement with Dole, prospective funding from marketing additional genes and additional contributions from our largest shareholder will provide the necessary liquidity to meet our obligations as they come due over the next year. We expect that the funding from these sources will be more than enough to cover our obligations for the next twelve months. However, if the funding does not arrive, the Company may not be able to meet its obligations as they become due.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Caution Regarding Forward-Looking Information

This report includes “forward-looking statements” that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements including continued compliance with government regulations, changing legislation or regulatory environments; any statements of expectation or belief and any statements of assumptions underlying any of the foregoing. These risks, uncertainties and other factors, and the general risks associated with the businesses of the Company described in the reports and other documents filed with the SEC, could cause actual results to differ materially from those referred to in the forward-looking statements. The Company cautions readers not to rely on these forward-looking statements. All forward-looking statements are based on information currently available to the Company and are qualified in their entirety by this cautionary statement. The Company anticipates that subsequent events and developments may cause its views to change. The information contained in this report speaks as of the date hereof and the Company has or undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise unless required by law.

Company Overview

Evolutionary Genomics, Inc. (the "registrant" or "Company") was incorporated under the laws of the state of Minnesota in November 1990 under the name Fonahome Corporation. On March 24, 2009, the Company reincorporated in the state of Nevada and merged with its wholly-owned subsidiary, Fona, Inc., adopting the surviving company’s name, Fona, Inc. and simultaneously adopted the capital structure of Fona Inc., which includes total authorized capital stock of 800,000,000 shares, of which 780,000,000 are common stock and 20,000,000 are blank check preferred stock. The preferred stock may be issued from time to time in one or more series with such designations, preferences and relative participating, optional or other special rights and qualifications, limitations or restrictions thereof, as shall be stated in the resolutions adopted by the Corporation’s Board providing for the issuance of such preferred stock or series thereof.

On June 6, 2014, Evolutionary Genomics, Inc., a Delaware corporation merged with Fona, Inc. treated as a reverse acquisition with Evolutionary Genomics, Inc. as the acquirer and Fona as the acquired party. Subsequent to the Merger, Fona, Inc. was renamed Evolutionary Genomics, Inc. and our subsidiary was renamed from Evolutionary Genomics, Inc. to EG Crop Science, Inc. On May 9, 2016, we formed ICAM Therapeutics, Inc. (a Delaware corporation) as a wholly owned subsidiary of Evolutionary Genomics, Inc. We have not incurred any transactions in this company nor have we established any business plan for the future.

The Company maintains headquarters at the office of its Chief Executive Officer. The Company maintains a website at www.evolgen.com. The Company is not required to deliver an annual report to security holders and at this time does not anticipate the distribution of such a report. The Company will file reports with the SEC.

On August 14, 2000, the Company was issued patent number 6274319, titled “Methods to identify evolutionarily significant changes in polynucleotide and polypeptide sequences in domestic plants and animals”. On June 1, 2004, the Company was issued patent number 6743580, titled “Methods for producing transgenic plants containing evolutionarily significant polynucleotides”. These patents are for the core Adapted Traits Platform that we use for the discovery of genes in humans, animals and commercial crops. The Company has applied the Adapted Traits Platform in research projects including identifying genes believed to be responsible for increases in yield in corn, increases in yield in rice, salt tolerance and sugar content in tomatoes and pest/disease resistance in soybeans, bananas and multiple other crops.

In the past century, agriculture has been characterized by enhanced productivity, the use of synthetic fertilizers and pesticides, selective breeding, mechanization, water contamination, and farm subsidies. Proponents of organic farming such as Sir Albert Howard argued in the early 20th century that the overuse of pesticides and synthetic fertilizers damages the long-term fertility of the soil. While this feeling lay dormant for decades, as environmental awareness has increased in the 21st century there has been a movement towards sustainable agriculture by some farmers, consumers, and policymakers.

Advances in genetic research and modification of crop species have led to increased yield, drought tolerance and disease/pest resistance. These advances have also led to an increased concentration within the providers of seed and seedling plants to crop producers. The top seed and plantlet providers control much of the implementation of new crop varieties through patents and licensing agreements. Genetic traits providers, like Evolutionary Genomics, identify and develop genes that impact traits of interest to the industry and market those genes to these companies.

The single most valuable step in the process of crop improvement is the identification of the key genes that have the desired impact. EG set out to find genes in soybeans that impact pest and disease resistance. We identified two that showed promise and, in hairy root assays on one of these genes, EG261, at the University of Wisconsin – Madison, proved that EG261 impacted resistance. When we discussed these results with the larger seed companies, they indicated interest but wanted to see two generation, whole plant testing results before entering licensing negotiations. We have engaged the University of Missouri and the University of Wisconsin’s Wisconsin Crop Innovation Center (“UW”) to independently perform these validation studies for us.

As a small company restricted by our limited resources, we cannot afford to generate vast numbers of transformation plant lines, known as events. Moderate success is important enough to indicate that further optimization can lead to significantly improved results. We must prove that there is enough evidence to warrant additional trials by companies with vastly more resources to build on our success but the single most valuable step in this process is the identification of the gene that has the desired impact and we have identified two of these genes, EG261 and EG19.

On April 29, 2014, the United States Patent and Trademark Office issued patent 8,710,300 titled EXPRESSION OF DIRIGENT GENE EG261 AND ITS ORTHOLOGS AND PARALOGS ENHANCES PATHOGEN RESISTANCE IN PLANTS. On December 5, 2017 and March 3, 2020, the United States Patent and Trademark Office issued additional patents which extended the previous patent to include additional variations of the gene. During 2017, the Company was issued similar patents in Canada, Brazil and China and has additional patents pending in Argentina and India. On January 15, 2021, the Company filed a patent application on its second soybean pest/disease resistance gene, EG19, and has included that gene in its ongoing two generation, whole plant validation research. The Company has also discovered additional candidate genes that may impact pathogen resistance. There can be no assurance that any of these genes will be proven effective in validation testing or lead to licensing agreements or revenue.

We entered into a Service Agreement with UW under which they transformed soybeans using our genes and helped to establish the right combinations to achieve a range of expression. UW grew events from seven constructs of EG261 and EG19 in their greenhouses. These plants were harvested in May 2020 for generation T2 seeds. The seeds were transferred to the University of Missouri and testing began in November 2020. We have completed three cycles of planting, growing and testing and expect to complete another two to three cycles by late summer 2021. The results of the second cycle were discarded because of process issues but the results of the other two cycles were very promising with significant improvement in disease resistance observed in plants transformed with our genes.

If results from the next two or three cycles confirm these findings, the Company intends to enter negotiations for a long-term research collaboration and licensing agreement with seed companies. If these negotiations are successful, this type of agreement will likely have an upfront payment, milestone payments during their testing and a licensing royalty stream once the genes are incorporated into commercial seed lines. The testing phase includes field trials which may proceed for several years prior to generating licensing revenue. There are many risks in this process including some that are outside of Evolutionary Genomics’ control and there can be no guarantee that we will ever generate any revenue from these potential agreements.

The Company has identified pest/disease resistance genes in other commercially valuable crops. The Company is in various stages of projects identifying genes in tomatoes and corn that may lead to increased pest/disease resistance. If successful, we intend to market them to the seed industry. This strategy will require Evolutionary Genomics to incur significant research costs prior to any confirmation of commercial viability and there can be no guarantee that the desired results can be achieved or that commercialization can be reached.

During the 1950s the global banana industry was devastated by a disease (caused by Fusarium fungus) that effectively wiped out the predominate variety of commercial bananas know as Gros Michel leading to the development of the Cavendish banana, which makes up well over 90% of the commercial banana market today. Cavendish was resistant to the strain of Fusarium that wiped out the Gros Michel variety but, in recent years, is being challenged by a new race of Fusarium that threatens to, once again, devastate the global banana industry. This crisis is imminent and has no solution. The recent emergence of Panama Disease TR4 in the Western Hemisphere makes a swift solution to the crisis even more urgent. A substantial part of the banana market consists of exports from Central and South America to the United States.

In 2018, the Company began a project to identify genes in wild banana relatives that are resistant to Fusarium. We used our platform to isolate a banana gene that controls Fusarium Wilt (FW), aka Panama Disease, Tropical Race 4. The gene, which we have named FusR1 (Fusarium Resistance 1), is a native gene in Musa species, including cultivated bananas. We have found that, for all FW-resistant banana cultivars/species that we have tested, one version of our gene exists while, in all FW-sensitive banana cultivars/species that we have tested, there is a different version of FusR1. And notably, a third version exists in semi-resistant varieties that has allowed us to identify the particular nucleotide changes that are crucial for resistance to Fusarium Wilt.

We believe that this native banana gene can be introduced into cultivated bananas, particularly the Fusarium-sensitive Cavendish cultivar in order to make these cultivars resistant to Fusarium Wilt. Cavendish cultivars are sterile and seedless, but it should be possible to use MAB (marker assisted breeding), though perhaps difficult and time-consuming, to move FusR1 into Cavendish and other cultivated bananas. We believe that a gene transformation approach would be faster and easier. Given the threat of possible extinction for Cavendish, rapid approaches are not only warranted but essential and minimally genetically edited bananas will be accepted depending upon how the gene transfer is accomplished. Transfer of this native banana gene to cultivated bananas can also be accomplished with CRISPR technology, which allows a targeted, clean, and efficient transfer and which, as compared to more traditional genetic editing techniques, minimizes potential side effects. We believe that Cavendish bananas can be rendered Fusarium Wilt resistant by changing only a few base pairs. These sorts of minimal changes have been allowed by the USDA and FDA in several crops. Even in Europe, use of CRISPR technology has gained substantial traction.

On June 26, 2019, we filed a United States patent application titled IDENTIFICATION AND RESISTANCE GENES FROM WILD RELATIVES OF BANANA AND THEIR USES IN CONTROLLING PANAMA DISEASE. We are awaiting review of these patents by the United States Patent Office.

On August 19, 2020, the Company entered into the DCA with Dole for the development of plant varieties within the Musa genus of the Musaceae family (including the Cavendish variety of banana) that exhibit resistance to Fusarium Wilt Tropical Race 4 (popularly known as Panama Disease). Subject to compliance with various provisions of the agreement, the agreement includes working capital funding from Dole to the Company over the next four years. In addition to working capital funding, Dole will reimburse the Company for the development of banana plants and incur additional costs for the commercialization of plants upon successful completion of the development portion of this project. In the year ended December 31, 2020, the Company received $800,000 of working capital funding and $1,295,831 of reimbursement of development costs pursuant to this agreement. Per the Agreement, 50% of future royalties may be offset with the research funding provided by Dole. In the event that Dole terminates the agreement for material breach by the Company or the Company’s bankruptcy, the Company must repay all funding provided by Dole within six months of termination. The parties have agreed to negotiate the terms of the long-term license agreement upon successful completion of the development portion of this project.

If we are able to successfully transform and validate our banana genes, which will likely take 24-36 months from the start of the project in September 2020, under the terms of the agreement with Dole, we expect to negotiate a long-term royalty contract for the commercialization of banana plants using our genes. This licensing arrangement will likely be exclusively with Dole and contain royalty payments based on the number of plants and/or hectares of plants. Even if EG’s genes are proven to be effective, it is difficult to predict the future revenue stream that any licensing arrangement can generate and will be heavily dependent upon the speed with which Panama Disease spreads throughout the world necessitating a solution and any changes in the price of bananas based on supply and demand. Many articles are available in the public realm detailing the significance of the disease and the spread throughout the world.

Since bananas are seedless, they are propagated by clones which allows for very rapid production of plants. An initial batch of 100 successful plants can generate a secondary propagation of over 15,000 plants in one year (enough for 10 hectares) and 15 million in the next generation. There are over 400,000 hectares of banana production in Latin America from Mexico to Peru. Adoption of the new variety will be dependent upon its effectiveness and the infection rate of Panama disease.

There are many risks associated with achieving these desired results including but not limited to:

	-	We may not be able to adequately establish patent protection for our intellectual property or others may have competing claims.
	-	Others may develop competitive approaches to compete with our genes.
	-	Our transformation academic labs may fail to develop enough events for testing.
	-	Our genes may cause unforeseen and undesirable changes beyond the pest resistance such as yield degradation or changes in the appearance or taste of the fruit.

	-	Our genes may fail to deliver the desired results of resistance to Fusarium.
	-	Globally regulations and/or consumer preference may prevent the successful commercial launch of bananas with genetics changed using our methods.
	-	We will be dependent on others for the successful production and marketing of bananas with our genes and many factors will be outside of our control.
	-	Our cash flow is highly dependent upon our only expected source of funding provided under our Development and Commercialization Agreement with Dole Food Company.
	-	Our expected future royalty revenue will be highly dependent upon the successful execution of the banana development project in the DCA with Dole and the negotiation of a long-term royalty licensing agreement expected in the third year of that agreement.

These and other risk factors are discussed in more detail in our 10-K filing dated March 31, 2021.

Evolutionary Genomics has no registered trademarks. The Company had two full time employees and one part-time employee as of March 31, 2021 and leases its operating facility on a month-to-month basis after June 30, 2017. Evolutionary Genomics is not currently involved in or aware of any threatened or actual legal proceedings.

Unaudited Results of Operations

	Three Months Ended March 31,
	2021					2020
	Amount			Percent of Revenue		Amount			Percent of Revenue
Grant revenue	$	—			N/A	$	12,500			100.0	%
Research and development		96,815			N/A		93,222			745.8	%
Salaries and benefits		92,430			N/A		92,430			739.4	%
General and administrative		324,605			N/A		56,665			453.3	%
Total operating expenses		513,850			N/A		242,317			1938.5	%
Operating (loss)		(513,850	)		N/A		(229,817	)		(1838.5	)%
Other income and (expenses)		108			N/A		(11,999	)		(96.0	)%
Income Taxes		—			N/A		—			0.0	%
Net loss	$	(513,742	)		N/A	$	(241,816	)		(1934.5	)%
Preferred stock dividend		(71,392	)		N/A		(71,391	)		(571.1	)%
Net loss attributable to common stockholders	$	(585,134	)		N/A	$	(313,207	)		(2505.7	)%

Grant Revenue

Grant revenue decreased $12,500, or 100.0%, to $0 for the three months ended March 31, 2021 from $12,500 for the three months ended March 31, 2020. The decrease was due to decreased revenue recognized from the State of Colorado grant which ended in January 2020.

Operating Expenses

Operating expenses increased $271,533, or 112.1% to $513,850 for the three months ended March 31, 2021 from $242,317 for the three months ended March 31, 2020. Changes in these items are described below.

Research and Development

Research and development increased $3,593, or 3.9%, to $96,815 for the three months ended March 31, 2021 from $93,222 for the three months ended March 31, 2020. The increase was primarily due to increased costs for our banana disease resistance project.

Salaries and Benefits

Salaries and benefits was unchanged at $92,430 for the three months ended March 31, 2021 and 2020.

General and Administrative

General and administrative expenses increased $267,940, or 472.8%, to $324,605 for the three months ended March 31, 2021 from $56,665 for the three months ended March 31, 2020. The increase was primarily due to the amortization of our research in progress which was placed into service August 19, 2020.

Other Income

Total other income increased $12,107, or 100.9%, to $108 for the three months ended March 31, 2021 from ($11,999) for the three months ended March 31, 2020. The loss in the three months ended March 31, 2020 was due to an unrealized loss in our investments which were sold in December 2020.

Net Loss

Net loss increased $271,926, or 112.5%, to $513,742 for the three months ended March 31, 2021 from $241,816 for the three months ended March 31, 2020. The increase was primarily due to the amortization of our research in progress and decrease in grant revenue.

Financial Condition

The Company’s working capital decreased $122,714 to $151,715 as of March 31, 2021 from $274,429 as of December 31, 2020 primarily due to the operating loss partially offset by proceeds of notes payable.

Liquidity

The Company has historically financed operations through debt and equity transactions. Net cash used in operating activities was $194,673 for the three months ended March 31, 2021 compared to $34,788 for the three months ended March 31, 2020. The $159,885, or 459.6%, increase was primarily due to the increased net operating loss and a decrease in accounts payable outstanding. Net cash provided from financing activities was $76,395 from notes payable from the PPP loan in the three months ended March 31, 2021. As of March 31, 2021, the Company had $97,558 in bank accounts. The Company’s current projections for cash required in operations over the twelve months ending March 31, 2022 is $1,323,669. This raises substantial doubt as to the Company’s ability to continue as a going concern.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements that have a material current effect, or that are reasonably likely to have a material future effect, on its financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures, or capital resources.

Contractual Obligations

The Company leases its operating facility and pays its rent in monthly installments. The lease was renewed in June 2016 for a period of twelve months and monthly rentals for the period of July 1, 2016 through March 31, 2021 are $2,378 per month which continues on a month-to-month basis. There is no minimum lease commitment as of March 31, 2021. Renewals after June 30, 2017 are by mutual agreement. The Company’s rent expense for the three months ended March 31, 2021 and 2020 was $7,134.

On September 18, 2020, the Company entered into a Standard Research Agreement with UW for the development of our banana genes. The agreement includes payments from the Company in the amount of $2,159,719 over the two-year expected term of the project. These costs will be reimbursed, in the form of notes payable by Dole in accordance with our DCA.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required by smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures.

The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives. Furthermore, smaller reporting companies such as the Company face additional limitations. Smaller reporting companies employ fewer individuals and find it difficult to properly segregate duties. Often, one or two individuals control every aspect of our operation and are in a position to override any system of internal control. Additionally, smaller reporting companies tend to utilize general accounting software packages that lack a rigorous set of software controls.

Our management, with the participation of the Chief Executive Officer, evaluated the effectiveness of our internal control over financial reporting as of March 31, 2021. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control — 2013 Integrated Framework. Based on this evaluation, our management, with the participation of the President, concluded that, as of December 31, 2020, our internal control over financial reporting was not effective due to the material weaknesses in the system of internal control described below.

Specifically, management identified the following control deficiencies: (1) the Company has not properly segregated duties as one or two individuals initiate, authorize, and complete all transactions. The Company has not implemented measures that would prevent the individuals from overriding the internal control system. The Company does not believe that this control deficiency has resulted in deficient financial reporting because the Chief Financial Officer is aware of his responsibilities under the SEC’s reporting requirements and personally certifies the financial reports. (2) The Company has installed accounting software that does not prevent erroneous or unauthorized changes to previous reporting periods and does not provide an adequate audit trail of entries made in the accounting software. (3) Due to the size of the Company and limited personnel, the Company has not hired an individual with technical accounting expertise within the accounting function.

(b) Changes in internal controls.

Our Certifying Officers have indicated that there were no changes in our internal controls over financial reporting or other factors that could significantly affect such controls subsequent to the date of his evaluation, and there were no such control actions with regard to significant deficiencies and material weaknesses.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 1A. RISK FACTORS

Impacts of COVID-19 on our business

The impact of a novel strain of coronavirus (COVID-19), and measures to prevent its spread are affecting the macroeconomic environment and while the full impact is uncertain, our business and results of operations could be materially adversely affected. We previously expected to complete the soybean research in the second quarter of 2020. During the second quarter of 2020, our academic labs informed us that they were not starting any new projects due to the COVID-19 pandemic. As of October 2020, the project is underway. If this research is not completed within a reasonable timeframe or within estimated costs, future licensing revenue, the valuation of our research in progress and the financial condition of the Company could be significantly impacted. The impact on our business will depend on a number of factors such as the duration and extent of COVID-19, governmental actions, changes in consumer behavior, responses of our third-party business partners that offer our content through their platforms, and general economic activity.

We are attempting to conduct business as usual to the extent possible and are complying with the applicable orders issued by the Governor of Colorado. The Company has been granted the status of essential operations and our staff continues to work in our lab while staggering working hours to limit exposure.

The impact of the COVID-19 outbreak may also exacerbate other risks discussed in Item 1A. Risk Factors in our Annual Report on Form 10-K, any of which could have a material effect on us.

ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

31.1		Rule 13a-14(a)/15d-14(a) Certification

31.2		Rule 13a-14(a)/15d-14(a) Certification

32.1		Section 1350 Certification

101		XBRL Interactive Data File

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this quarterly report to be signed on its behalf by the undersigned, thereunto duly authorized.

	EVOLUTIONARY GENOMICS, INC.


BY:	/s/ Steve B Warnecke
	Steve B Warnecke
	Chief Executive Officer and Chief Financial Officer

	May 13, 2021

EX-31.1 2 fnam_ex31z1.htm CERTIFICATIONS Certification

EXHIBIT 31.1

CERTIFICATIONS

I, Steve Warnecke, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Evolutionary Genomics, Inc.

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting, to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


	May 13, 2021

BY:	/s/ Steve Warnecke
	Steve Warnecke
	Chief Executive Officer
	(principal executive officer)

EX-31.1 3 fnam_ex31z2.htm CERTIFICATIONS Certification

EXHIBIT 31.2

CERTIFICATIONS

I, Steve Warnecke, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Evolutionary Genomics, Inc.

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


	May 13, 2021

BY:	/s/ Steve Warnecke
	Steve Warnecke
	Chief Financial Officer
	(principal financial officer)

EX-32.1 4 fnam_ex32z1.htm CERTIFICATION Certification

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Evolutionary Genomics, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Steve B Warnecke, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. section1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


BY:	/s/ Steve B Warnecke
	Steve B Warnecke
	Chief Executive Officer and Chief Financial Officer
	(principal executive and financial officer)
	May 13, 2021

EX-101.INS 5 fnam-20200331.xml XBRL INSTANCE FILE 0000884363 2015-10-19 0000884363 srt:MinimumMember 2021-01-01 2021-03-31 0000884363 srt:MaximumMember 2021-01-01 2021-03-31 0000884363 us-gaap:ConvertiblePreferredStockMember 2015-10-19 0000884363 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-03-31 0000884363 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0000884363 2021-01-01 2021-03-31 0000884363 srt:ChiefExecutiveOfficerMember 2021-03-31 0000884363 2020-01-01 2020-03-31 0000884363 us-gaap:PatentsMember 2021-01-01 2021-03-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000884363 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000884363 fnam:ConvertiblePreferredStockSeriesA2Member 2020-05-01 0000884363 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-03-31 0000884363 fnam:ConvertiblePreferredStockSeriesA2Member 2021-01-01 2021-03-31 0000884363 us-gaap:CommonStockMember 2020-12-31 0000884363 us-gaap:CommonStockMember 2021-03-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000884363 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000884363 us-gaap:RetainedEarningsMember 2020-12-31 0000884363 us-gaap:RetainedEarningsMember 2021-03-31 0000884363 2020-12-31 0000884363 2021-03-31 0000884363 us-gaap:SeriesAPreferredStockMember 2021-03-31 0000884363 us-gaap:SeriesAPreferredStockMember 2020-12-31 0000884363 fnam:SeriesA2PreferredStockMember 2021-03-31 0000884363 fnam:SeriesA2PreferredStockMember 2020-12-31 0000884363 us-gaap:EquipmentMember 2020-12-31 0000884363 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-12-31 0000884363 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000884363 us-gaap:EquipmentMember 2021-03-31 0000884363 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-03-31 0000884363 us-gaap:FurnitureAndFixturesMember 2021-03-31 0000884363 us-gaap:InProcessResearchAndDevelopmentMember 2021-03-31 0000884363 us-gaap:PatentsMember 2021-03-31 0000884363 us-gaap:InProcessResearchAndDevelopmentMember 2020-12-31 0000884363 us-gaap:PatentsMember 2020-12-31 0000884363 us-gaap:PatentsMember 2020-01-01 2020-03-31 0000884363 2020-01-01 2020-12-31 0000884363 us-gaap:ConvertibleDebtSecuritiesMember 2020-01-01 2020-03-31 0000884363 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0000884363 fnam:CommonStockAndWarrantsMember 2020-01-01 2020-03-31 0000884363 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000884363 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000884363 us-gaap:CommonStockMember 2019-12-31 0000884363 us-gaap:CommonStockMember 2020-03-31 0000884363 fnam:PreferredDividendMember 2021-01-01 2021-03-31 0000884363 fnam:PreferredDividendMember 2020-01-01 2020-03-31 0000884363 fnam:PreferredDividendMember 2020-12-31 0000884363 fnam:PreferredDividendMember 2021-03-31 0000884363 fnam:PreferredDividendMember 2019-12-31 0000884363 fnam:PreferredDividendMember 2020-03-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000884363 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000884363 us-gaap:RetainedEarningsMember 2019-12-31 0000884363 us-gaap:RetainedEarningsMember 2020-03-31 0000884363 2019-12-31 0000884363 2020-03-31 0000884363 fnam:SBAPaycheckProtectionProgramMember 2021-02-01 2021-02-22 0000884363 fnam:EconomicInjuryDisasterLoanMember 2020-06-04 2020-06-05 0000884363 fnam:DCADoleMember 2020-08-19 0000884363 fnam:ResearchAgreementUniversityOfWisconsinMadisonMember 2020-09-18 0000884363 fnam:EIDLProgramMember 2020-06-04 2020-06-05 0000884363 fnam:EIDLProgramMember 2021-03-31 0000884363 fnam:EIDLProgramMember 2020-06-05 0000884363 fnam:SBAPaycheckProtectionProgramMember 2021-02-22 0000884363 fnam:StandardResearchAgreementMember 2020-09-01 2020-09-18 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure

0.001

780000000

4016596

52045

4016596

52045

251687

651

7134

54930

1081667

1.74

800000000

20000000

600000

200000

20000000

600000

200000

.001

0.001

P3Y

P7Y

65000

350520

3569594

3029579

540015

577063

102860

577063

102860

4272380

622457

5881898

1902088 0.2945

P20Y

54930

-71391

-71392

71392

71391

404298

655985

0.08

5881898 EVOLUTIONARY GENOMICS, INC. 0000884363 10-Q 2021-03-31 false --12-31 Non-accelerated Filer true false false Q1 2021 Yes Yes NV 000-54129 0.7516

503665

432499

63179

7987

432499

63179

7987

452902

460918

8016

9529

P10Y

1400000

2378 262400 393600 5.25 5.25 5.25 5.25

1307620

P6Y8M2D

P7Y8M2D

2248995

2326361

2245831

2322226

3164

4135

3164

4135

3992699

3611253

3715106

3455403

3664343

3412656

50763

42747

277593

155850

61757

58292

1236228

1307620

3992699

3611253

5882

12015552

11999090

-15083552

-15597294

-1825890

-2284702

5882

1236228

1307620

950661

1022052

12081401

12064940

-13371669

-13613485

-333725

-520611

-15083552

-15597294

12015552

11999090

5882

5881898

-0.10

-0.05

-585134

-313207

71392

71391

-513742

-241816

-513742

-241816

108

-11999

108

-513850

-229817

513850

242317

324605

56665

92430

96815

93222

12500

71392 71391

215836

97558

45441

10653

76395

3000

150000

-194673

-34788

971

114160

-3465

-8913

-6845

-12000

54930

259703

10180

-118278

-34788

679923

1081667

679923

1081667

110856

3383

2602

638105

1006751

755064

1793

731

0.0375

0.01

4135

800000 800000 250000 250000 2200000 2159719 750000 5050000

688332

1.85

P6Y5M1D P6Y8M2D

P5Y2M8D

2159719

P2Y

Note 1: Business Activity   Evolutionary Genomics, Inc. (the “Company,” “We,” or “Our”) has developed a technology platform, the Adapted Traits Platform (“ATP”), to identify commercially valuable genes that control important traits in animals and plants. We are using the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. Our platform identifies key genes that have changed successfully to impart new or improved traits.   In the past, the Company performed research on behalf of governmental organizations, non-profit foundations and commercial entities and received revenue from grants and commercial research contracts. We have not received any revenue from these grant arrangements since early 2020. The Company now focuses on research projects that may lead to long-term licensing arrangements with agricultural seed companies and crop producers as with our soybean and banana projects. These projects take several years to develop, and successful commercialization may take many years to produce license royalty payments. Our banana project, in cooperation with Dole Food Company is an example that has resulted in notes payable funding for the development phase of our banana genes and may result in a long-term royalty bearing license once the development phase is complete.   During 2014, the Company purchased 75.16% of the outstanding stock of Fona, Inc., (“Fona”) a public shell company. Since Fona was a public shell company which did not constitute a business and the purchase was done in contemplation of a reverse merger, the Company accounted for the payment as a distribution to Fona shareholders. The Company also entered into an Agreement and Plan of Merger (the “Merger”), which was consummated on October 19, 2015. As a result of the Merger, Evolutionary Genomics, Inc. became a wholly owned subsidiary of Fona. For accounting purposes, the merger was treated as a reverse acquisition with Evolutionary Genomics, Inc. as the acquirer and Fona as the acquired party. Subsequent to the Merger, Fona was renamed Evolutionary Genomics, Inc. and our subsidiary was renamed from Evolutionary Genomics, Inc. to EG Crop Science, Inc.

Note 2: Summary of Significant Accounting Policies   Principals of Consolidation: These consolidated financial statements include the accounts of Evolutionary Genomics, Inc. and its wholly owned subsidiary. All material intercompany transactions and balances have been eliminated.   Use of Estimates: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.   These consolidated financial statements have been prepared on the basis of going concern. Management’s plans to address the Company’s liquidity are discussed further in Note 13.   Cash: The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less when purchased to be cash.   Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided for by the straight-line method over three- to seven-year estimated useful lives for software, furniture and fixtures and equipment. Maintenance and repairs are expensed as incurred; major renewals and betterments that extend the useful lives of property and equipment are capitalized. When property and equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is recognized.   Long-Lived Assets: The long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. An impairment loss is measured and recorded to the extent that the carrying amount of the asset exceeds its estimated fair value. No asset impairment was recorded during the three months ended March 31, 2021 and 2020.   Intangible Assets: Intangible assets include acquired research in progress and patents on the Company’s core technology for gene identification. Patents are amortized over their expected useful life of 20 years using the straight-line method. Acquired research in progress was placed into service on August 19, 2020 in conjunction with the Development and Commercialization Agreement and is being amortized over four years consistent with the term of the Dole agreement using the straight-line method. Costs incurred to renew intangible assets are expensed in the period incurred, while costs incurred to extend the lives of patents are capitalized and amortized over the remaining useful life of the asset. Intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any intangible assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. No impairment was recorded during the three months ended March 31, 2021 and 2020.   Revenue Recognition: Grant revenue consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by us. However, these amounts are subject to change upon review by federal and non-profit foundations prior to receipt of invoice amounts submitted. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed.   Income Taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Management regularly assesses the likelihood that deferred tax assets will be recovered from future taxable income, and to the extent management believes that it is more likely than not that a deferred tax asset will not be realized, a valuation allowance is established. When a valuation allowance is established, increased or decreased, an income tax charge or benefit is included in the consolidated financial statements and net deferred tax assets are adjusted accordingly. As of March 31, 2021 and December 31, 2020, a full valuation allowance has been established on the net deferred tax asset.   Under the Income Tax topic of the ASC, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company has no accruals for uncertain tax benefits.   Stock-Based Compensation: The Company accounts for stock option awards in accordance with ASC 718. The estimated grant-date fair value of stock-based awards is expensed over the requisite service period, which is typically equivalent to the vesting term of the award.   The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services received follows the provisions of ASC Topic 718. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement.   Research and Development: Research and development costs are expensed as incurred. In instances where we enter into agreements with third parties for research and development activities, we may prepay for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed.   Net Loss Per Common Share: Basic net (loss) income per common share excludes any dilutive effects of equity instruments. We compute basic net (loss) income per common share using the weighted average number of common shares outstanding during the period. We compute diluted net (loss) income per common share using the weighted average number of common shares and common stock equivalents outstanding during the period. For the three months ended March 31, 2021, common stock equivalents including 679,923 shares of convertible preferred stock and options for 1,081,667 shares of common stock were excluded because their effect was anti-dilutive. For the three months ended March 31, 2020, common stock equivalents including 679,923 shares of convertible preferred stock, options for 1,081,667 shares of common stock and warrants for 110,856 shares of common stock were excluded because their effect was anti-dilutive.

Note 3: New Accounting Standards   Recently Issued Accounting Standards   In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments,” which requires entities to estimate all expected credit losses for certain types of financial instruments, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The updated guidance also expands the disclosure requirements to enable users of financial statements to understand the entity’s assumptions, models and methods for estimating expected credit losses over the entire contractual term of the instrument from the date of initial recognition of that instrument. This guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within that reporting period and is not expected to have an impact on the Company’s consolidated financial statements.

Note 7: Notes Payable   Small Business Administration (“SBA”) Paycheck Protection Program (“PPP”): On February 22, 2021, the Company received $76,395 in proceeds from the PPP, which was created under the Coronavirus Aid, Relief and Economic Security Act (CARES). Under the program, the Company may apply for forgiveness of the debt based on the use of the proceeds over an 8-week or a 24-week period following funding of the loan. To the extent that the loan is not forgiven, the loan accrues interest at 1 percent and has monthly payments of $1,792.53 starting July 22, 2022. The Company expects this loan to be forgiven within the year ending December 31, 2021 after it meets the requirements of the forgiveness provisions.   SBA Economic Injury Disaster Loan: On June 5, 2020, the Company received a $3,000 Economic Injury Disaster Loan (“EIDL”) advance and $150,000 in proceeds from the SBA’s EIDL Program. Installment payments, including interest at the rate of 3.75% per annum, of $731 monthly over thirty years from the date of the promissory note will begin twelve months from the date of the promissory note (June 5, 2022). The Company granted to the SBA a continuing security interest in all tangible and intangible personal property. The Company may not make any distribution of assets of the Company to any shareholder without the written consent of the SBA. As of March 31, 2021, the Company recognized $4,135 of accrued interest on the note.   Dole Food Company:   On August 19, 2020, the Company entered into a Development and Commercialization Agreement (“DCA”) with Dole Food Company (“Dole”) for the development of our banana genes. The DCA provides for payments from Dole to the Company of $800,000 upon execution, $800,000 by the twelve-month anniversary (August 19, 2021), $250,000 by the thirty-six month anniversary and $250,000 by the forty-eight month anniversary. Dole will also reimburse the Company for costs incurred at the University of Wisconsin-Madison (“UW”) not to exceed $2,200,000 in coordination with the Standard Research Agreement that the Company entered into with UW on September 18, 2020. The agreement with UW includes payments from the Company to UW in the amount of $2,159,719 over the two-year expected term of the project. If the UW research is successful, Dole expects to incur costs of approximately $750,000 to perform field trials.   The DCA also specifies that the Company will execute notes payable to Dole for the funding that Dole is providing up to $5,050,000. Upon receipt of $800,000 on August 26, 2020 and $1,295,831 on December 29, 2020, the Company executed the notes under this DCA and recorded them as long-term notes payable for financial statement purposes. The notes are non-interest bearing and allow Dole to offset fifty percent of future royalty payments to the Company by reducing the amount of principal due on these notes. Other than this offset of future royalty payments, repayment of principal and interest is only required in the case of termination of the DCA by Dole for cause.

Note 8: Stockholders’ Equity and Warrants   The Amended and Restated Certificate of Incorporation of the Company dated October 19, 2015 authorized the issuance of 800,000,000 shares of all classes of stock including 780,000,000 shares of Common Stock having a par value of $0.001 per share and 20,000,000 shares of Preferred Stock having a par value of $0.001 per share, 600,000 of which were designated as Series A-1 Convertible Preferred Stock (“Series A-1”) and 200,000 of which were designated as Series A-2 Convertible Preferred Stock (“Series A-2”). The Board of Directors, without a vote of the shareholders, is authorized to issue additional shares of Preferred Stock in series and to establish the characteristics thereof.   Liquidation: Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of the Series A-1 and Series A-2 shall be entitled to receive out of the assets of the Company for each share of Series A-1 and Series A-2 an amount equal to its stated value, $5.25 per share as of March 31, 2021 and December 31, 2020, plus any accrued but unpaid dividends before any distribution or payment shall be made to the holders of any other class or series of stock of the Company that ranks junior to the Series A-1 and Series A-2. The holders shall be entitled to convert their shares of Series A-1 and Series A-2 into Common Stock at any time prior to the consummation of a Liquidation. This is considered a contingent redemption feature.   Conversion: The holders of Series A-1 and Series A-2 may convert their shares into shares of Common Stock, at the option of the holder, on a one-share-for-one-share basis and shall be subject to certain adjustments at any time.   Optional Redemption; Sinking Fund Account: The Company may elect to redeem some or all of the then outstanding shares of Series A-1, (i) for cash in an amount equal to the liquidation preference per share, $5.25 per share as of March 31, 2021, subject to adjustment and (ii) by issuing one share, subject to adjustment, of Common Stock for each share of Series A-1 and Series A-2 outstanding being redeemed. 50% of all licensing fees received by the Company will be deposited into a separate sinking fund for use in an optional redemption. As of March 31, 2021, no licensing revenue has been received under these provisions and no sinking fund account has been established.   Dividends: The Company shall pay to the holders of the Series A-1 and Series A-2 dividends at the rate of 8% per annum and the Company has accrued these dividends since issuance of the Series A-1 and Series A-2. The dividend amount shall accrue and shall be payable in shares of Common Stock upon the conversion of the Series A-1 and Series A-2, or upon the redemption of the Series A-1 and Series A-2. No dividends shall be paid on any Common Stock of the Company or any capital stock of the Company that ranks junior to the Series A-1 and Series A-2 until dividends of Series A-1 and Series A-2 been paid. As of March 31, 2021, there were $1,307,620 in accrued stock dividends.   Voting: The holders of the Series A-1 and Series A-2 are entitled to vote on all matters submitted to the stockholders for a vote on an as-if-converted to Common Stock basis, with all stockholders voting as a single class.

Note 10: Commitments and Contingencies   Officer Indemnification: Under the Company’s organizational documents, the Company’s officers, employees, and directors are indemnified against certain liabilities arising out of the performance of their duties. The Company’s maximum exposure under these arrangements is unknown, as this would involve future claims that may be made against the Company that have not yet occurred. However, based on experience, the Company expects any risk of loss to be remote. The Company also has an insurance policy for its directors and officers to insure them against liabilities arising from their performance in their positions with the Company.   Lease Commitments: The Company leases its operating facility and pays its rent in monthly installments. The lease was renewed in June 2016 for a period of twelve months and monthly rentals for the period of July 1, 2016 through March 31, 2021 are $2,378 per month which continues on a month-to-month basis. There is no minimum lease commitment as of March 31, 2021. Renewals after June 30, 2017 are by mutual agreement. The Company’s rent expense for the three months ended March 31, 2021 and 2020 was $7,134.   Royalty: Effective March 1, 2012, the Company entered into an Agreement for Contract Services with SmithBucklin Corporation (the “Contractor”) on behalf of the United Soybean Board. The contract includes the payment of certain royalties, as defined in the Agreement   The Company is obligated to pay royalties to the United Soybean Board of 10% of the sale of products derived from the soybean genes that were the subject of the research performed by the Contractor or from royalties received by the Company from the sale of products by a third party not to exceed 150% of the total amount paid to the Contractor under this Agreement. The Company has recognized to date grant revenue from the contract of $262,400 as of March 31, 2021, thus limiting any future royalties as of March 31, 2021 to a total of $393,600. The Company has not accrued or paid any royalties under the terms of the Agreement as of and during the three months ended March 31, 2021 because it has not received any revenue from the sale of products to date.   Other Commitments: On September 18, 2020, the Company entered into a Standard Research Agreement with UW for the development of our banana genes. The agreement includes payments from the Company in the amount of $2,159,719 over the two-year expected term of the project. These costs will be reimbursed, in the form of notes payable by Dole in accordance with our DCA.

Note 11: Related Parties and Transactions   Steve B. Warnecke: Mr. Warnecke is the Company’s Chief Executive Officer and Chairman of the Board and owns, directly or indirectly, 1,902,088 shares or 29.45% of the Common Stock outstanding as of March 31, 2021.

Note 12: Concentrations   Considerations of Credit Risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains its cash balances at high-credit, quality financial institutions. The balances, at times, may exceed federally insured limits. The Company routinely monitors the credit quality of its customers.

Note 13: Liquidity   As of March 31, 2021, the Company had $97,558 in bank accounts. The Company’s current projections for cash required in operations over the twelve months ending March 31, 2022 is $1,323,669. This raises substantial doubt as to the Company’s ability to continue as a going concern.   To address these factors, management believes that it will secure additional funding to meet prospective cash requirements. Management believes the Company’s existing cash balances along with funding from our agreement with Dole, prospective funding from marketing additional genes and additional contributions from our largest shareholder will provide the necessary liquidity to meet our obligations as they come due over the next year. We expect that the funding from these sources will be more than enough to cover our obligations for the next twelve months. However, if the funding does not arrive, the Company may not be able to meet its obligations as they become due.

Principals of Consolidation: These consolidated financial statements include the accounts of Evolutionary Genomics, Inc. and its wholly owned subsidiary. All material intercompany transactions and balances have been eliminated.

Use of Estimates: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.   These consolidated financial statements have been prepared on the basis of going concern. Management’s plans to address the Company’s liquidity are discussed further in Note 13.

Cash: The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less when purchased to be cash.

Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided for by the straight-line method over three- to seven-year estimated useful lives for software, furniture and fixtures and equipment. Maintenance and repairs are expensed as incurred; major renewals and betterments that extend the useful lives of property and equipment are capitalized. When property and equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is recognized.

Long-Lived Assets: The long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. An impairment loss is measured and recorded to the extent that the carrying amount of the asset exceeds its estimated fair value. No asset impairment was recorded during the three months ended March 31, 2021 and 2020.

Intangible Assets: Intangible assets include acquired research in progress and patents on the Company’s core technology for gene identification. Patents are amortized over their expected useful life of 20 years using the straight-line method. Acquired research in progress was placed into service on August 19, 2020 in conjunction with the Development and Commercialization Agreement and is being amortized over four years consistent with the term of the Dole agreement using the straight-line method. Costs incurred to renew intangible assets are expensed in the period incurred, while costs incurred to extend the lives of patents are capitalized and amortized over the remaining useful life of the asset. Intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any intangible assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. No impairment was recorded during the three months ended March 31, 2021 and 2020.

Revenue Recognition: Grant revenue consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by us. However, these amounts are subject to change upon review by federal and non-profit foundations prior to receipt of invoice amounts submitted. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed.

Income Taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Management regularly assesses the likelihood that deferred tax assets will be recovered from future taxable income, and to the extent management believes that it is more likely than not that a deferred tax asset will not be realized, a valuation allowance is established. When a valuation allowance is established, increased or decreased, an income tax charge or benefit is included in the consolidated financial statements and net deferred tax assets are adjusted accordingly. As of March 31, 2021 and December 31, 2020, a full valuation allowance has been established on the net deferred tax asset.   Under the Income Tax topic of the ASC, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company has no accruals for uncertain tax benefits.

Stock-Based Compensation: The Company accounts for stock option awards in accordance with ASC 718. The estimated grant-date fair value of stock-based awards is expensed over the requisite service period, which is typically equivalent to the vesting term of the award.   The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services received follows the provisions of ASC Topic 718. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement.

Research and Development: Research and development costs are expensed as incurred. In instances where we enter into agreements with third parties for research and development activities, we may prepay for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed.

Net Loss Per Common Share: Basic net (loss) income per common share excludes any dilutive effects of equity instruments. We compute basic net (loss) income per common share using the weighted average number of common shares outstanding during the period. We compute diluted net (loss) income per common share using the weighted average number of common shares and common stock equivalents outstanding during the period. For the three months ended March 31, 2021, common stock equivalents including 679,923 shares of convertible preferred stock and options for 1,081,667 shares of common stock were excluded because their effect was anti-dilutive. For the three months ended March 31, 2020, common stock equivalents including 679,923 shares of convertible preferred stock, options for 1,081,667 shares of common stock and warrants for 110,856 shares of common stock were excluded because their effect was anti-dilutive.

5881898

1323669

65333

Note 4: Fair Value Measurements   The Company complies with the provisions of ASC 820, in measuring fair value and in disclosing fair value measurements at the measurement date. ASC 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements required under other accounting pronouncements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements also reflect the assumptions market participants would use in pricing an asset or liability based on the best information available. Assumptions include the risks inherent in a particular valuation technique (such as a pricing model) and/or the risks inherent in the inputs to the model.   ASC 820 provides three levels of the fair value hierarchy as described below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%"> </td> <td style="width: 13%">Level 1 Inputs</td> <td style="width: 1%">–</td> <td style="width: 81%">Quoted prices (unadjusted) in active markets for identical assets or liabilities.</td></tr> <tr style="vertical-align: top"> <td> </td> <td>Level 2 Inputs</td> <td>–</td> <td style="text-align: justify">Observable market-based inputs, other than quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="vertical-align: top"> <td> </td> <td>Level 3 Inputs</td> <td>–</td> <td>Unobservable inputs that are supported by little or no market activity.</td></tr> </table>   When determining the fair value measurements for assets or liabilities required or permitted to be recorded at and/or marked to fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability. When possible, the Company looks to active and observable markets to price identical assets. When identical assets are not traded in active markets, the Company looks to market observable data for similar assets.   The carrying value of financial instruments, including cash, receivables, accounts payable, and accrued expenses, approximates their fair value at March 31, 2021 and December 31, 2020, due to the relatively short-term nature of these instruments.

Note 5: Property and Equipment   Property and equipment is comprised of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">March 31,</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">December 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2021</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2020</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="width: 74%">Equipment</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">432,499</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">432,499</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Software</td> <td> </td> <td> </td> <td style="text-align: right">63,179</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">63,179</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="padding-bottom: 1pt">Furniture and fixtures</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,987</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,987</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">503,665</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">503,665</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="padding-bottom: 1pt">Accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(460,918</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(452,902</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Property and equipment, net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">42,747</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">50,763</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Depreciation expense for the three months ended March 31, 2021 and 2020 was $8,016 and $9,529, respectively.

Note 6: Intangible Assets   Intangible assets are comprised of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">March 31,</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">December 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2021</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2020</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="width: 74%">Acquired research in progress - definite lived</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">4,016,596</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">4,016,596</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Patents</td> <td> </td> <td> </td> <td style="text-align: right">52,045</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">52,045</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="padding-bottom: 1pt">Accumulated amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(655,985</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(404,298</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Intangible assets, net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,412,656</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,664,343</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   The Company expects to recognize amortization expense related to its acquired research in progress and patents according to the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Year Ending</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Amortization</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="width: 81%">December 31, 2021</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">755,064</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>December 31, 2022</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,006,751</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td>December 31, 2023</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,006,751</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>December 31, 2024</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">638,105</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td>December 31, 2025</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,602</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Thereafter</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,383</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,412,656</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Amortization expense for the acquired research in progress and patents during the three months ended March 31, 2021 and 2020 was $251,687 and $651, respectively.   In its merger completed on October 19, 2015, the Company acquired research in progress. The value of the acquired research in progress was based upon several factors including, evaluation of other intangible assets, the purchase price, estimated future cash flows, and the amounts expended on the research to date. The research in progress was the identification and validation of genes to provide pest and disease resistance to plants performed by EG I. With the banana development project contract in place and the expected marketing of our soybean genes in mid-2021, the Company placed this asset in service on August 19, 2020. Additional costs to complete the soybean research are expected to be approximately $65,000, which will be expensed as incurred. The timing and cost of additional research may vary from these estimates as the success of the research is subject to many factors outside of the Company’s control.

Note 9: Stock-Based Compensation   The Company grants stock-based instruments under the 2015 Stock Incentive Plan (“Plan”) for which 1,400,000 shares of the Company’s Common Stock has been reserved. The Plan allows for the issuance of incentive stock options and non-qualified stock options with a maximum contractual term of 10 years. Shares and options that are cancelled are available for reissuance under the Plan. For three months ended March 31, 2021 and 2020, the Company recorded compensation costs for stock options of $54,930. Stock options are generally issued with an exercise price at or above the estimated per-share value of the Company’s Common Stock. The Company granted no options during the three months ended March 31, 2021 and 2020.   Management has valued the options at their date of grant utilizing the Black-Scholes option pricing model. As of the issuance of the outstanding options, there was not a public market for the Company’s shares. Accordingly, the Company utilized the value obtained in equity transactions with unrelated parties to estimate the fair value of the Company’s Common Stock on the date of grant. Volatility of the underlying common shares was determined based on the historical volatility for similar companies that are actively traded in the public markets for a term consistent with the expected life of the options. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options on the date of the grant. Due to the lack of sufficient historical activity, the expected life of the options was estimated using the formula set forth in Securities and Exchange Commission SAB 107.   The following table summarizes the status of the Company’s aggregate stock options granted:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of   Options</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Term(Years)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total Intrinsic Value</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="width: 31%">Balance, January 1, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">1,081,667</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">1.74</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">7.67</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td>Exercised</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Cancelled</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Balance, December 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,081,667</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1.74</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6.67</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Balance, January 1, 2021</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,081,667</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.74</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.67</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td>Granted</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td>Cancelled</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="padding-bottom: 2.5pt">Balance, March 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,081,667</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1.74</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6.42</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">688,332</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1.85</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5.19</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">65,333</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   During the three months ended March 31, 2021 and 2020, options for 0 and 0 shares vested, respectively. As of March 31, 2021 there was $350,520 of unrecognized compensation cost related to share-based compensation arrangements that will be recognized through the year ending December 31, 2022.

The following table summarizes the status of the Company’s aggregate stock options granted:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of   Options</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Term(Years)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total Intrinsic Value</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="width: 31%">Balance, January 1, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">1,081,667</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">1.74</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">7.67</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td>Exercised</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Cancelled</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Balance, December 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,081,667</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1.74</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6.67</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Balance, January 1, 2021</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,081,667</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.74</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.67</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td>Granted</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td>Cancelled</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="padding-bottom: 2.5pt">Balance, March 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,081,667</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1.74</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6.42</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">688,332</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1.85</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5.19</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">65,333</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The Company expects to recognize amortization expense related to its acquired research in progress and patents according to the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Year Ending</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Amortization</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="width: 81%">December 31, 2021</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">755,064</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>December 31, 2022</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,006,751</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td>December 31, 2023</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,006,751</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>December 31, 2024</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">638,105</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td>December 31, 2025</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,602</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Thereafter</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,383</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,412,656</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Intangible assets are comprised of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">March 31,</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">December 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2021</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2020</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="width: 74%">Acquired research in progress - definite lived</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">4,016,596</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">4,016,596</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Patents</td> <td> </td> <td> </td> <td style="text-align: right">52,045</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">52,045</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="padding-bottom: 1pt">Accumulated amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(655,985</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(404,298</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Intangible assets, net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,412,656</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,664,343</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Property and equipment is comprised of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">March 31,</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">December 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2021</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2020</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="width: 74%">Equipment</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">432,499</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">432,499</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Software</td> <td> </td> <td> </td> <td style="text-align: right">63,179</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">63,179</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="padding-bottom: 1pt">Furniture and fixtures</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,987</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,987</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">503,665</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">503,665</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCFFCC"> <td style="padding-bottom: 1pt">Accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(460,918</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(452,902</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Property and equipment, net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">42,747</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">50,763</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

EX-101.SCH 6 fnam-20200331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed and Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed and Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed and Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed and Consolidated Statement of Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed and Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Business Activity link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - New Accounting Standards link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stockholders' Equity and Warrants link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Related Parties and Transactions link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Concentrations link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Business Activity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Intangible Assets (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Intangible Assets (Details Narrtive) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Stockholders' Equity and Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Stock-Based Compensation (Summary of Stock Options Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Related Parties and Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Liquidity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 fnam-20200331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 fnam-20200331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 fnam-20200331_lab.xml XBRL LABEL FILE Range [Axis] Minimum [Member] Maximum [Member] Class of Stock [Axis] Series A-1 Convertible Preferred Stock [Member] Antidilutive Securities [Axis] Convertible Preferred Stock [Member] Stock Options [Member] Related Party Transaction [Axis] Chief Executive Officer [Member] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Equity Components [Axis] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Series A-2 Convertible Preferred Stock [Member] Common Stock [Member] Series A-1 Convertible Preferred Stock [Member] Series A-2 Convertible Preferred Stock [Member] Property, Plant and Equipment, Type [Axis] Equipment [Member] Software [Member] Furniture and fixtures [Member] Acquired research in progress [Member] Common Stock and Warrants [Member] Common Stock Preferred Dividend Additional Paid-In Capital Accumulated Deficit Debt Instrument [Axis] SBA Paycheck Protection Program [Member[ Economic Injury Disaster Loan [Member[ DCA with Dole Food Company [Member[ Research Agreement University of Wisconsin Madison [Member[ EIDL Program [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Standard Research Agreement Document And Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Current Reporting Status Entity Interactive Data Current Entity Incorporation State Country Name Entity File Number Statement [Table] Statement [Line Items] ASSETS Current assets Cash Prepaid expenses Total current assets Non-current assets Property and equipment, net Intangible assets, net Total non-current assets Total assets LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY Current liabilities Accounts payable and accrued expenses Total current liabilities Long-term liabilities Notes payable Total liabilities Commitments and contingencies Total preferred stock subject to possible redemption Stockholders' deficit Preferred Stock Common Stock, $0.001 par value; 780,000,000 shares authorized, 5,881,898 shares issued and outstanding at March 31, 2021 and December 31, 2020 Additional paid-in capital Accumulated deficit Total stockholders' deficit Total liabilities and stockholders' deficit Preferred stock, par value Preferred stock, authorized shares Preferred stock, issued shares Preferred stock, outstanding shares Preferred stock, liquidation preference Common stock, par value Common stock, authorized shares Common stock, issued shares Common stock, outstanding shares Income Statement [Abstract] Grant revenue Operating expenses Research and development Salaries and benefits General and administrative Total operating expenses Operating loss Other income (expenses): Investment income Unrealized loss on investments Total other income (expenses) Loss before income taxes Income taxes Net loss Preferred stock dividend Net loss attributable to common stockholders Net loss per common share, basic and diluted Weighted average common shares outstanding, basic and diluted Balance Balance, shares Stock compensation Preferred stock dividends Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash flows from operating activities Depreciation and amortization Stock-based compensation Unrealized loss on investments Changes in operating assets and liabilities: Accounts receivable Prepaid expenses Accounts payable and accrued expenses Cash flows from operating activities Cash flows from investing activities: Cash flows from investing activities Cash flows from financing activities: Proceeds from issuance of notes payable Cash flows from financing activities Net change in cash Cash, beginning of period Cash, end of period Supplemental cash flow information Preferred stock dividend accrual Organization, Consolidation and Presentation of Financial Statements [Abstract] Business Activity Accounting Policies [Abstract] Summary of Significant Accounting Policies Accounting Changes and Error Corrections [Abstract] New Accounting Standards Fair Value Disclosures [Abstract] Fair Value Measurements Property, Plant and Equipment [Abstract] Property and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Debt Disclosure [Abstract] Notes Payable Equity [Abstract] Stockholders' Equity and Warrants Share-based Payment Arrangement [Abstract] Stock-Based Compensation Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Related Party Transactions [Abstract] Related Parties and Transactions Risks and Uncertainties [Abstract] Concentrations Liquidity and Going Concern Principals of Consolidation Use of Estimates Cash Property and Equipment Long-Lived Assets Intangible Assets Revenue Recognition Income Taxes Stock-Based Compensation Research and Development Net Loss Per Common Share Schedule of Property and Equipment Schedule of Intangible Assets Schedule of Intangible Assets Amortization Schedule of Stock Option Activity Percentage of outstanding stock purchased during reverse merger with Fona, Inc. Statistical Measurement [Axis] Estimated useful lives of property and equipment Intangible assets useful lives Antidilutive shares excluded from earnings per share calculation Asset impairment charges Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Long-Lived Tangible Asset [Axis] Property and equipment, gross Accumulated depreciation Property and equipment, net Depreciation expense Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Intangible assets, gross Intangible assets, accumulated amortization December 31, 2021 EX-101.PRE 10 fnam-20200331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2021 shares
Document And Entity Information [Abstract]
Entity Registrant Name	EVOLUTIONARY GENOMICS, INC.
Entity Central Index Key	0000884363
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	5,881,898
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Incorporation State Country Name	NV
Entity File Number	000-54129

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed and Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets
Cash	$ 97,558	$ 215,836
Prepaid expenses	58,292	61,757
Total current assets	155,850	277,593
Non-current assets
Property and equipment, net	42,747	50,763
Intangible assets, net	3,412,656	3,664,343
Total non-current assets	3,455,403	3,715,106
Total assets	3,611,253	3,992,699
Current liabilities
Accounts payable and accrued expenses	4,135	3,164
Total current liabilities	4,135	3,164
Long-term liabilities
Notes payable	2,322,226	2,245,831
Total liabilities	2,326,361	2,248,995
Total preferred stock subject to possible redemption	3,569,594	3,569,594
Stockholders' deficit
Preferred Stock	1,307,620	1,236,228
Common Stock, $0.001 par value; 780,000,000 shares authorized, 5,881,898 shares issued and outstanding at March 31, 2021 and December 31, 2020	5,882	5,882
Additional paid-in capital	11,999,090	12,015,552
Accumulated deficit	(15,597,294)	(15,083,552)
Total stockholders' deficit	(2,284,702)	(1,825,890)
Total liabilities and stockholders' deficit	3,611,253	3,992,699
Series A-1 Convertible Preferred Stock [Member]
Long-term liabilities
Total preferred stock subject to possible redemption	3,029,579	3,029,579
Series A-2 Convertible Preferred Stock [Member]
Long-term liabilities
Total preferred stock subject to possible redemption	$ 540,015	$ 540,015

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed and Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized shares	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized shares	780,000,000	780,000,000
Common stock, issued shares	5,881,898	5,881,898
Common stock, outstanding shares	5,881,898	5,881,898
Series A-1 Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized shares	600,000	600,000
Preferred stock, issued shares	577,063	577,063
Preferred stock, outstanding shares	577,063	577,063
Preferred stock, liquidation preference	$ 4,272,380
Series A-2 Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized shares	200,000	200,000
Preferred stock, issued shares	102,860	102,860
Preferred stock, outstanding shares	102,860	102,860
Preferred stock, liquidation preference	$ 622,457

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed and Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Grant revenue	$ 0	$ 12,500
Operating expenses
Research and development	96,815	93,222
Salaries and benefits	92,430	92,430
General and administrative	324,605	56,665
Total operating expenses	513,850	242,317
Operating loss	(513,850)	(229,817)
Other income (expenses):
Investment income	108	1
Unrealized loss on investments	0	(12,000)
Total other income (expenses)	108	(11,999)
Loss before income taxes	(513,742)	(241,816)
Income taxes	0	0
Net loss	(513,742)	(241,816)
Preferred stock dividend	(71,392)	(71,391)
Net loss attributable to common stockholders	$ (585,134)	$ (313,207)
Net loss per common share, basic and diluted	$ (0.10)	$ (0.05)
Weighted average common shares outstanding, basic and diluted	5,881,898	5,881,898

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed and Consolidated Statement of Stockholders' Deficit (Unaudited) - USD ($)	Common Stock	Preferred Dividend	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2019	$ 5,882	$ 950,661	$ 12,081,401	$ (13,371,669)	$ (333,725)
Balance, shares at Dec. 31, 2019	5,881,898
Stock compensation			54,930		54,930
Preferred stock dividends		71,391	(71,391)
Net loss				(241,816)	(241,816)
Balance at Mar. 31, 2020	$ 5,882	1,022,052	12,064,940	(13,613,485)	(520,611)
Balance, shares at Mar. 31, 2020	5,881,898
Balance at Dec. 31, 2020	$ 5,882	1,236,228	12,015,552	(15,083,552)	(1,825,890)
Balance, shares at Dec. 31, 2020	5,881,898
Stock compensation			54,930		54,930
Preferred stock dividends		71,392	(71,392)
Net loss				(513,742)	(513,742)
Balance at Mar. 31, 2021	$ 5,882	$ 1,307,620	$ 11,999,090	$ (15,597,294)	$ (2,284,702)
Balance, shares at Mar. 31, 2021	5,881,898

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed and Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (513,742)	$ (241,816)
Adjustments to reconcile net loss to net cash flows from operating activities
Depreciation and amortization	259,703	10,180
Stock-based compensation	54,930	54,930
Unrealized loss on investments	0	12,000
Changes in operating assets and liabilities:
Accounts receivable	0	6,845
Prepaid expenses	3,465	8,913
Accounts payable and accrued expenses	971	114,160
Cash flows from operating activities	(194,673)	(34,788)
Cash flows from investing activities:
Cash flows from investing activities	0	0
Cash flows from financing activities:
Proceeds from issuance of notes payable	76,395	0
Cash flows from financing activities	76,395	0
Net change in cash	(118,278)	(34,788)
Cash, beginning of period	215,836	45,441
Cash, end of period	97,558	10,653
Supplemental cash flow information
Preferred stock dividend accrual	$ 71,392	$ 71,391

XML 17 R7.htm IDEA: XBRL DOCUMENT

Business Activity

3 Months Ended

Mar. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Activity

Note 1: Business Activity

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2: Summary of Significant Accounting Policies

These consolidated financial statements have been prepared on the basis of going concern. Management’s plans to address the Company’s liquidity are discussed further in Note 13.

Cash: The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less when purchased to be cash.

XML 19 R9.htm IDEA: XBRL DOCUMENT

New Accounting Standards

3 Months Ended

Mar. 31, 2021

Accounting Changes and Error Corrections [Abstract]

New Accounting Standards

Note 3: New Accounting Standards

Recently Issued Accounting Standards

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (c)

+ Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 4: Fair Value Measurements

ASC 820 provides three levels of the fair value hierarchy as described below:

Level 1 Inputs	–	Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 Inputs	–	Observable market-based inputs, other than quoted prices in active markets for identical assets or liabilities.
Level 3 Inputs	–	Unobservable inputs that are supported by little or no market activity.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Property and Equipment

3 Months Ended

Mar. 31, 2021

Property, Plant and Equipment [Abstract]

Property and Equipment

Note 5: Property and Equipment

Property and equipment is comprised of the following:

	March 31,			December 31,
	2021			2020
Equipment	$	432,499		$	432,499
Software		63,179			63,179
Furniture and fixtures		7,987			7,987
		503,665			503,665
Accumulated depreciation		(460,918	)		(452,902	)
Property and equipment, net	$	42,747		$	50,763

Depreciation expense for the three months ended March 31, 2021 and 2020 was $8,016 and $9,529, respectively.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Intangible Assets

3 Months Ended

Mar. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Note 6: Intangible Assets

Intangible assets are comprised of the following:

	March 31,			December 31,
	2021			2020
Acquired research in progress - definite lived	$	4,016,596		$	4,016,596
Patents		52,045			52,045
Accumulated amortization		(655,985	)		(404,298	)
Intangible assets, net	$	3,412,656		$	3,664,343

The Company expects to recognize amortization expense related to its acquired research in progress and patents according to the following:

Year Ending	Amortization
December 31, 2021	$	755,064
December 31, 2022		1,006,751
December 31, 2023		1,006,751
December 31, 2024		638,105
December 31, 2025		2,602
Thereafter		3,383
Total	$	3,412,656

Amortization expense for the acquired research in progress and patents during the three months ended March 31, 2021 and 2020 was $251,687 and $651, respectively.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Notes Payable

3 Months Ended

Mar. 31, 2021

Debt Disclosure [Abstract]

Notes Payable

Note 7: Notes Payable

Dole Food Company:

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

Stockholders' Equity and Warrants

3 Months Ended

Mar. 31, 2021

Equity [Abstract]

Stockholders' Equity and Warrants

Note 8: Stockholders’ Equity and Warrants

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

3 Months Ended

Mar. 31, 2021

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

Note 9: Stock-Based Compensation

The following table summarizes the status of the Company’s aggregate stock options granted:

	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Term(Years)		Total Intrinsic Value

Balance, January 1, 2020		1,081,667	$	1.74		7.67
Granted		—		—		—
Exercised		—		—		—
Cancelled		—		—		—

Balance, December 31, 2020		1,081,667	$	1.74		6.67

Balance, January 1, 2021		1,081,667	$	1.74		6.67
Granted		—		—		—
Exercised		—		—		—
Cancelled		—		—		—

Balance, March 31, 2021		1,081,667	$	1.74		6.42	$	—

Exercisable at March 31, 2021		688,332	$	1.85		5.19	$	65,333

XML 26 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2021

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 10: Commitments and Contingencies

XML 27 R17.htm IDEA: XBRL DOCUMENT

Related Parties and Transactions

3 Months Ended

Mar. 31, 2021

Related Parties and Transactions

Note 11: Related Parties and Transactions

XML 28 R18.htm IDEA: XBRL DOCUMENT

Concentrations

3 Months Ended

Mar. 31, 2021

Risks and Uncertainties [Abstract]

Concentrations

Note 12: Concentrations

XML 29 R19.htm IDEA: XBRL DOCUMENT

Liquidity

3 Months Ended

Mar. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Liquidity and Going Concern

Note 13: Liquidity

XML 30 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2021
Accounting Policies [Abstract]
Principals of Consolidation	Principals of Consolidation: These consolidated financial statements include the accounts of Evolutionary Genomics, Inc. and its wholly owned subsidiary. All material intercompany transactions and balances have been eliminated.
Use of Estimates	Use of Estimates: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. These consolidated financial statements have been prepared on the basis of going concern. Management’s plans to address the Company’s liquidity are discussed further in Note 13.
Cash	Cash: The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less when purchased to be cash.
Property and Equipment	Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided for by the straight-line method over three- to seven-year estimated useful lives for software, furniture and fixtures and equipment. Maintenance and repairs are expensed as incurred; major renewals and betterments that extend the useful lives of property and equipment are capitalized. When property and equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is recognized.
Long-Lived Assets	Long-Lived Assets: The long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. An impairment loss is measured and recorded to the extent that the carrying amount of the asset exceeds its estimated fair value. No asset impairment was recorded during the three months ended March 31, 2021 and 2020.
Intangible Assets	Intangible Assets: Intangible assets include acquired research in progress and patents on the Company’s core technology for gene identification. Patents are amortized over their expected useful life of 20 years using the straight-line method. Acquired research in progress was placed into service on August 19, 2020 in conjunction with the Development and Commercialization Agreement and is being amortized over four years consistent with the term of the Dole agreement using the straight-line method. Costs incurred to renew intangible assets are expensed in the period incurred, while costs incurred to extend the lives of patents are capitalized and amortized over the remaining useful life of the asset. Intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any intangible assets may be impaired, an evaluation of recoverability is performed. An impairment is considered to exist if the total estimated undiscounted cash flows are less than the carrying amount of the asset. No impairment was recorded during the three months ended March 31, 2021 and 2020.
Revenue Recognition	Revenue Recognition: Grant revenue consists of funding under cost reimbursement programs primarily from federal and non-profit foundation sources for qualified research and development activities performed by us. However, these amounts are subject to change upon review by federal and non-profit foundations prior to receipt of invoice amounts submitted. Such amounts are invoiced and recorded as revenue as grant-funded activities are performed.
Income Taxes	Income Taxes: Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Management regularly assesses the likelihood that deferred tax assets will be recovered from future taxable income, and to the extent management believes that it is more likely than not that a deferred tax asset will not be realized, a valuation allowance is established. When a valuation allowance is established, increased or decreased, an income tax charge or benefit is included in the consolidated financial statements and net deferred tax assets are adjusted accordingly. As of March 31, 2021 and December 31, 2020, a full valuation allowance has been established on the net deferred tax asset. Under the Income Tax topic of the ASC, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company has no accruals for uncertain tax benefits.
Stock-Based Compensation	Stock-Based Compensation: The Company accounts for stock option awards in accordance with ASC 718. The estimated grant-date fair value of stock-based awards is expensed over the requisite service period, which is typically equivalent to the vesting term of the award. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services received follows the provisions of ASC Topic 718. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement.
Research and Development	Research and Development: Research and development costs are expensed as incurred. In instances where we enter into agreements with third parties for research and development activities, we may prepay for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed.
Net Loss Per Common Share	Net Loss Per Common Share: Basic net (loss) income per common share excludes any dilutive effects of equity instruments. We compute basic net (loss) income per common share using the weighted average number of common shares outstanding during the period. We compute diluted net (loss) income per common share using the weighted average number of common shares and common stock equivalents outstanding during the period. For the three months ended March 31, 2021, common stock equivalents including 679,923 shares of convertible preferred stock and options for 1,081,667 shares of common stock were excluded because their effect was anti-dilutive. For the three months ended March 31, 2020, common stock equivalents including 679,923 shares of convertible preferred stock, options for 1,081,667 shares of common stock and warrants for 110,856 shares of common stock were excluded because their effect was anti-dilutive.

XML 31 R21.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2021

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment is comprised of the following:

	March 31,			December 31,
	2021			2020
Equipment	$	432,499		$	432,499
Software		63,179			63,179
Furniture and fixtures		7,987			7,987
		503,665			503,665
Accumulated depreciation		(460,918	)		(452,902	)
Property and equipment, net	$	42,747		$	50,763

XML 32 R22.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets are comprised of the following:

	March 31,			December 31,
	2021			2020
Acquired research in progress - definite lived	$	4,016,596		$	4,016,596
Patents		52,045			52,045
Accumulated amortization		(655,985	)		(404,298	)
Intangible assets, net	$	3,412,656		$	3,664,343

Schedule of Intangible Assets Amortization

The Company expects to recognize amortization expense related to its acquired research in progress and patents according to the following:

Year Ending	Amortization
December 31, 2021	$	755,064
December 31, 2022		1,006,751
December 31, 2023		1,006,751
December 31, 2024		638,105
December 31, 2025		2,602
Thereafter		3,383
Total	$	3,412,656

XML 33 R23.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2021

Share-based Payment Arrangement [Abstract]

Schedule of Stock Option Activity

The following table summarizes the status of the Company’s aggregate stock options granted:

	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Term(Years)		Total Intrinsic Value

Balance, January 1, 2020		1,081,667	$	1.74		7.67
Granted		—		—		—
Exercised		—		—		—
Cancelled		—		—		—

Balance, December 31, 2020		1,081,667	$	1.74		6.67

Balance, January 1, 2021		1,081,667	$	1.74		6.67
Granted		—		—		—
Exercised		—		—		—
Cancelled		—		—		—

Balance, March 31, 2021		1,081,667	$	1.74		6.42	$	—

Exercisable at March 31, 2021		688,332	$	1.85		5.19	$	65,333

XML 34 R24.htm IDEA: XBRL DOCUMENT

Business Activity (Details Narrative)	3 Months Ended
Business Activity (Details Narrative)	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Percentage of outstanding stock purchased during reverse merger with Fona, Inc.	75.16%

XML 35 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Asset impairment charges	$ 0	$ 0
Convertible Preferred Stock [Member]
Antidilutive shares excluded from earnings per share calculation	679,923	679,923
Stock Options [Member]
Antidilutive shares excluded from earnings per share calculation	1,081,667	1,081,667
Common Stock and Warrants [Member]
Antidilutive shares excluded from earnings per share calculation		110,856
Patents [Member]
Intangible assets useful lives	20 years
Minimum [Member]
Estimated useful lives of property and equipment	3 years
Maximum [Member]
Estimated useful lives of property and equipment	7 years

XML 36 R26.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 503,665	$ 503,665
Accumulated depreciation	(460,918)	(452,902)
Property and equipment, net	42,747	50,763
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	432,499	432,499
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	63,179	63,179
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 7,987	$ 7,987

XML 37 R27.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 8,016	$ 9,529

XML 38 R28.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Intangible assets, accumulated amortization	$ (655,985)	$ (404,298)
Intangible assets, net	3,412,656	3,664,343
Acquired research in progress [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	4,016,596	4,016,596
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 52,045	$ 52,045

XML 39 R29.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details 1) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
December 31, 2021	$ 755,064
December 31, 2022	1,006,751
December 31, 2023	1,006,751
December 31, 2024	638,105
December 31, 2025	2,602
Thereafter	3,383
Total	$ 3,412,656	$ 3,664,343

XML 40 R30.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details Narrtive) - USD ($)	3 Months Ended
Intangible Assets (Details Narrtive) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Additional expected costs to complete research	$ 65,000
Patents [Member]
Amortization expense	$ 251,687	$ 651

XML 41 R31.htm IDEA: XBRL DOCUMENT

Notes Payable (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended
Notes Payable (Details Narrative) - USD ($)	Jun. 05, 2020	Feb. 22, 2021	Mar. 31, 2021	Mar. 31, 2020	Sep. 18, 2020	Aug. 19, 2020
Proceeds			$ 76,395	$ 0
SBA Paycheck Protection Program [Member[
Proceeds		$ 76,395
Monthly payment		$ 1,793
Interest rate		1.00%
Economic Injury Disaster Loan [Member[
Proceeds	$ 3,000
EIDL Program [Member]
Proceeds	150,000
Monthly payment	$ 731
Interest rate	3.75%
Accrued interest			$ 4,135
DCA with Dole Food Company [Member[
Payment upon execution						$ 800,000
Payment twelve month anniversary						800,000
Payment thirty six month anniversary						250,000
Payment forty eight month anniversary						250,000
Reimbursement of costs						2,200,000
Expected field trial costs						750,000
Notes payable for Dole funding						$ 5,050,000
Research Agreement University of Wisconsin Madison [Member[
Expected payments University of Wisconsin-Madison					$ 2,159,719

XML 42 R32.htm IDEA: XBRL DOCUMENT

Stockholders' Equity and Warrants (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	May 01, 2020	Oct. 19, 2015
Class of Stock [Line Items]
Capital stock, authorized shares				800,000,000
Common stock, authorized shares	780,000,000	780,000,000		780,000,000
Common stock, par value	$ 0.001	$ 0.001		$ 0.001
Preferred stock, authorized shares	20,000,000	20,000,000		20,000,000
Preferred stock, par value	$ 0.001	$ 0.001		$ .001
Dividends accrued	$ 1,307,620
Series A-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, authorized shares				600,000
Preferred stock, par value				$ 0.001
Dividend rate	8.00%
Series A-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, authorized shares	600,000	600,000
Preferred stock, par value	$ 0.001	$ 0.001
Stated per share value of preferred stock	$ 5.25	$ 5.25
Series A-2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, authorized shares	200,000	200,000
Preferred stock, par value	$ 0.001	$ 0.001
Stated per share value of preferred stock	$ 5.25	$ 5.25
Series A-2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, authorized shares			200,000
Dividend rate	8.00%

XML 43 R33.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Summary of Stock Options Activity) (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Number of Options
Balance, beginning	1,081,667	1,081,667
Granted
Exercised
Cancelled
Balance, ending	1,081,667	1,081,667
Exercisable	688,332
Weighted Average Exercise Price
Balance, beginning	$ 1.74	$ 1.74
Granted
Exercised
Cancelled
Balance, ending	1.74	$ 1.74
Exercisable	$ 1.85
Weighted Average Remaining Term(Years)
Outstanding beginning, contractual term	6 years 8 months 2 days	7 years 8 months 2 days
Outstanding ending, contractual term	6 years 5 months 1 day	6 years 8 months 2 days
Exercisable, contractual term	5 years 2 months 8 days
Total Intrinsic Value
Outstanding, intrinsic value	$ 0
Exercisable, intrinsic value	$ 65,333

XML 44 R34.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details Narrative) - USD ($)	3 Months Ended
Stock-Based Compensation (Details Narrative) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Number of shares reserved for issuance under 2015 Stock Incentive Plan	1,400,000
Expiration period for stock options	10 years
Compensation costs for incentive stock options	$ 54,930	$ 54,930
Stock options granted during period	0	0
Number of shares vested during the period	0	0
Unrecognized compensation cost related to share-based compensation arrangements	$ 350,520

XML 45 R35.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Sep. 18, 2020	Mar. 31, 2021	Mar. 31, 2020
Monthly rent payment		$ 2,378
Rent expense		7,134	$ 7,134
Total amount of grant revenue recognized to date		262,400
Total possible future royalties owed		$ 393,600
Standard Research Agreement
Payments for royalties	$ 2,159,719
Term	2 years

XML 46 R36.htm IDEA: XBRL DOCUMENT

Related Parties and Transactions (Details Narrative) - Chief Executive Officer [Member]	Mar. 31, 2021 shares
Related Party Transaction [Line Items]
Number of common stock shares outstanding owned by related party	1,902,088
Percentage of common stock shares outstanding owned by related party	29.45%

XML 47 R37.htm IDEA: XBRL DOCUMENT

Liquidity (Details Narrative) - USD ($)	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 97,558	$ 215,836	$ 10,653	$ 45,441
Working Capital	$ 1,323,669

EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 49 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 69 247 1 false 25 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://evolutionarygenomicsinc.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed and Consolidated Balance Sheets (Unaudited) Sheet http://evolutionarygenomicsinc.com/role/AndConsolidatedBalanceSheets Condensed and Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed and Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://evolutionarygenomicsinc.com/role/AndConsolidatedBalanceSheetsParenthetical Condensed and Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed and Consolidated Statements of Operations (Unaudited) Sheet http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfOperations Condensed and Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed and Consolidated Statement of Stockholders' Deficit (Unaudited) Sheet http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementOfStockholdersDeficit Condensed and Consolidated Statement of Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed and Consolidated Statements of Cash Flows (Unaudited) Sheet http://evolutionarygenomicsinc.com/role/AndConsolidatedStatementsOfCashFlows Condensed and Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Business Activity Sheet http://evolutionarygenomicsinc.com/role/NatureOfBusiness Business Activity Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - New Accounting Standards Sheet http://evolutionarygenomicsinc.com/role/NewAccountingStandards New Accounting Standards Notes 9 false false R10.htm 00000010 - Disclosure - Fair Value Measurements Sheet http://evolutionarygenomicsinc.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 00000011 - Disclosure - Property and Equipment Sheet http://evolutionarygenomicsinc.com/role/PropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 00000012 - Disclosure - Intangible Assets Sheet http://evolutionarygenomicsinc.com/role/IntangibleAssets Intangible Assets Notes 12 false false R13.htm 00000013 - Disclosure - Notes Payable Notes http://evolutionarygenomicsinc.com/role/NotesPayable Notes Payable Notes 13 false false R14.htm 00000014 - Disclosure - Stockholders' Equity and Warrants Sheet http://evolutionarygenomicsinc.com/role/Disclosure-CommonStock Stockholders' Equity and Warrants Notes 14 false false R15.htm 00000015 - Disclosure - Stock-Based Compensation Sheet http://evolutionarygenomicsinc.com/role/Stock-basedCompensation Stock-Based Compensation Notes 15 false false R16.htm 00000016 - Disclosure - Commitments and Contingencies Sheet http://evolutionarygenomicsinc.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 00000017 - Disclosure - Related Parties and Transactions Sheet http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactions Related Parties and Transactions Notes 17 false false R18.htm 00000018 - Disclosure - Concentrations Sheet http://evolutionarygenomicsinc.com/role/Concentrations Concentrations Notes 18 false false R19.htm 00000019 - Disclosure - Liquidity Sheet http://evolutionarygenomicsinc.com/role/LiquidityAndGoingConcern Liquidity Notes 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://evolutionarygenomicsinc.com/role/fnam-soapadobp Summary of Significant Accounting Policies (Policies) Policies http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - Property and Equipment (Tables) Sheet http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://evolutionarygenomicsinc.com/role/PropertyAndEquipment 21 false false R22.htm 00000022 - Disclosure - Intangible Assets (Tables) Sheet http://evolutionarygenomicsinc.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://evolutionarygenomicsinc.com/role/IntangibleAssets 22 false false R23.htm 00000023 - Disclosure - Stock-Based Compensation (Tables) Sheet http://evolutionarygenomicsinc.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://evolutionarygenomicsinc.com/role/Stock-basedCompensation 23 false false R24.htm 00000024 - Disclosure - Business Activity (Details Narrative) Sheet http://evolutionarygenomicsinc.com/role/BusinessActivityDetailsNarrative Business Activity (Details Narrative) Details http://evolutionarygenomicsinc.com/role/NatureOfBusiness 24 false false R25.htm 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://evolutionarygenomicsinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://evolutionarygenomicsinc.com/role/fnam-soapadobp 25 false false R26.htm 00000026 - Disclosure - Property and Equipment (Details) Sheet http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentTables 26 false false R27.htm 00000027 - Disclosure - Property and Equipment (Details Narrative) Sheet http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://evolutionarygenomicsinc.com/role/PropertyAndEquipmentTables 27 false false R28.htm 00000028 - Disclosure - Intangible Assets (Details) Sheet http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://evolutionarygenomicsinc.com/role/IntangibleAssetsTables 28 false false R29.htm 00000029 - Disclosure - Intangible Assets (Details 1) Sheet http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetails1 Intangible Assets (Details 1) Details http://evolutionarygenomicsinc.com/role/IntangibleAssetsTables 29 false false R30.htm 00000030 - Disclosure - Intangible Assets (Details Narrtive) Sheet http://evolutionarygenomicsinc.com/role/IntangibleAssetsDetailsNarrtive Intangible Assets (Details Narrtive) Details http://evolutionarygenomicsinc.com/role/IntangibleAssetsTables 30 false false R31.htm 00000031 - Disclosure - Notes Payable (Details Narrative) Notes http://evolutionarygenomicsinc.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://evolutionarygenomicsinc.com/role/NotesPayable 31 false false R32.htm 00000032 - Disclosure - Stockholders' Equity and Warrants (Details Narrative) Sheet http://evolutionarygenomicsinc.com/role/StockholdersEquityAndWarrantsDetailsNarrative Stockholders' Equity and Warrants (Details Narrative) Details http://evolutionarygenomicsinc.com/role/Disclosure-CommonStock 32 false false R33.htm 00000033 - Disclosure - Stock-Based Compensation (Summary of Stock Options Activity) (Details) Sheet http://evolutionarygenomicsinc.com/role/Stock-basedCompensationSummaryOfStockOptionsActivityDetails Stock-Based Compensation (Summary of Stock Options Activity) (Details) Details http://evolutionarygenomicsinc.com/role/Stock-basedCompensationTables 33 false false R34.htm 00000034 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://evolutionarygenomicsinc.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://evolutionarygenomicsinc.com/role/Stock-basedCompensationTables 34 false false R35.htm 00000035 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://evolutionarygenomicsinc.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://evolutionarygenomicsinc.com/role/CommitmentsAndContingencies 35 false false R36.htm 00000036 - Disclosure - Related Parties and Transactions (Details Narrative) Sheet http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactionsDetailsNarrative Related Parties and Transactions (Details Narrative) Details http://evolutionarygenomicsinc.com/role/RelatedPartiesAndTransactions 36 false false R37.htm 00000037 - Disclosure - Liquidity (Details Narrative) Sheet http://evolutionarygenomicsinc.com/role/LiquidityDetailsNarrative Liquidity (Details Narrative) Details http://evolutionarygenomicsinc.com/role/LiquidityAndGoingConcern 37 false false All Reports Book All Reports fnam-20200331.xml fnam-20200331.xsd fnam-20200331_cal.xml fnam-20200331_def.xml fnam-20200331_lab.xml fnam-20200331_pre.xml http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 true true ZIP 53 0001553350-21-000382-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001553350-21-000382-xbrl.zip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end